nbx-20210630
FALSE0001760854--12-316/30/20212021Q20.33330.33330.3333P3Y0.130.070.380.330.280.350.300.260.740.690.630.5900017608542021-01-012021-06-30iso4217:EUR0001760854nbx:ServicesMember2021-01-012021-06-300001760854nbx:ServicesMember2020-01-012020-06-300001760854nbx:OtherSalesMember2021-01-012021-06-300001760854nbx:OtherSalesMember2020-01-012020-06-3000017608542020-01-012020-06-3000017608542021-06-3000017608542020-12-31iso4217:EURxbrli:sharesxbrli:shares0001760854ifrs-full:IssuedCapitalMember2020-12-310001760854ifrs-full:SharePremiumMember2020-12-310001760854ifrs-full:AccumulatedOtherComprehensiveIncomeMember2020-12-310001760854ifrs-full:TreasurySharesMember2020-12-310001760854ifrs-full:OtherReservesMember2020-12-310001760854nbx:NetLossForThePeriodMember2020-12-310001760854nbx:NetLossForThePeriodMember2021-01-012021-06-300001760854ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001760854ifrs-full:OtherReservesMember2021-01-012021-06-300001760854ifrs-full:IssuedCapitalMember2021-01-012021-06-300001760854ifrs-full:SharePremiumMember2021-01-012021-06-300001760854ifrs-full:TreasurySharesMember2021-01-012021-06-300001760854ifrs-full:IssuedCapitalMember2021-06-300001760854ifrs-full:SharePremiumMember2021-06-300001760854ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-06-300001760854ifrs-full:TreasurySharesMember2021-06-300001760854ifrs-full:OtherReservesMember2021-06-300001760854nbx:NetLossForThePeriodMember2021-06-300001760854ifrs-full:IssuedCapitalMember2019-12-310001760854ifrs-full:SharePremiumMember2019-12-310001760854ifrs-full:AccumulatedOtherComprehensiveIncomeMember2019-12-310001760854ifrs-full:TreasurySharesMember2019-12-310001760854ifrs-full:OtherReservesMember2019-12-310001760854nbx:NetLossForThePeriodMember2019-12-3100017608542019-12-310001760854nbx:NetLossForThePeriodMember2020-01-012020-06-300001760854ifrs-full:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-06-300001760854ifrs-full:OtherReservesMember2020-01-012020-06-300001760854ifrs-full:IssuedCapitalMember2020-01-012020-06-300001760854ifrs-full:SharePremiumMember2020-01-012020-06-300001760854ifrs-full:TreasurySharesMember2020-01-012020-06-300001760854ifrs-full:IssuedCapitalMember2020-06-300001760854ifrs-full:SharePremiumMember2020-06-300001760854ifrs-full:AccumulatedOtherComprehensiveIncomeMember2020-06-300001760854ifrs-full:TreasurySharesMember2020-06-300001760854ifrs-full:OtherReservesMember2020-06-300001760854nbx:NetLossForThePeriodMember2020-06-3000017608542020-06-30nbx:patent_familynbx:platformiso4217:USD0001760854srt:MaximumMembernbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member2021-03-310001760854nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member2021-03-012021-03-310001760854nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member2021-03-012021-06-30nbx:study0001760854nbx:LianBioNBTXR3Member2021-05-012021-05-310001760854nbx:LianBioNBTXR3Member2021-06-152021-06-150001760854nbx:LianBioNBTXR3Membersrt:MaximumMember2021-06-30nbx:subsidiaryxbrli:pure0001760854nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member2021-01-012021-06-300001760854nbx:LianBioNBTXR3Member2021-05-012021-06-300001760854nbx:EuropeanInvestmentBankLoanAgreementMembersrt:MaximumMember2018-07-310001760854nbx:EuropeanInvestmentBankLoanAgreementMember2018-07-012018-07-31nbx:patient0001760854nbx:MDAndersonCancerCenterNBTXR3Member2021-01-012021-06-300001760854nbx:MDAndersonCancerCenterNBTXR3Member2019-01-310001760854nbx:MDAndersonCancerCenterNBTXR3Member2021-06-300001760854ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMemberifrs-full:GrossCarryingAmountMember2020-12-310001760854ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMemberifrs-full:GrossCarryingAmountMember2021-01-012021-06-300001760854ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMemberifrs-full:GrossCarryingAmountMember2021-06-300001760854ifrs-full:ComputerSoftwareMemberifrs-full:GrossCarryingAmountMember2020-12-310001760854ifrs-full:ComputerSoftwareMemberifrs-full:GrossCarryingAmountMember2021-01-012021-06-300001760854ifrs-full:ComputerSoftwareMemberifrs-full:GrossCarryingAmountMember2021-06-300001760854ifrs-full:GrossCarryingAmountMemberifrs-full:IntangibleAssetsUnderDevelopmentMember2020-12-310001760854ifrs-full:GrossCarryingAmountMemberifrs-full:IntangibleAssetsUnderDevelopmentMember2021-01-012021-06-300001760854ifrs-full:GrossCarryingAmountMemberifrs-full:IntangibleAssetsUnderDevelopmentMember2021-06-300001760854ifrs-full:GrossCarryingAmountMember2020-12-310001760854ifrs-full:GrossCarryingAmountMember2021-01-012021-06-300001760854ifrs-full:GrossCarryingAmountMember2021-06-300001760854ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2020-12-310001760854ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2021-01-012021-06-300001760854ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2021-06-300001760854ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerSoftwareMember2020-12-310001760854ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerSoftwareMember2021-01-012021-06-300001760854ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerSoftwareMember2021-06-300001760854ifrs-full:AccumulatedDepreciationAndAmortisationMember2020-12-310001760854ifrs-full:AccumulatedDepreciationAndAmortisationMember2021-01-012021-06-300001760854ifrs-full:AccumulatedDepreciationAndAmortisationMember2021-06-300001760854ifrs-full:FixturesAndFittingsMemberifrs-full:GrossCarryingAmountMember2020-12-310001760854ifrs-full:FixturesAndFittingsMemberifrs-full:GrossCarryingAmountMember2021-01-012021-06-300001760854ifrs-full:FixturesAndFittingsMemberifrs-full:GrossCarryingAmountMember2021-06-300001760854ifrs-full:GrossCarryingAmountMembernbx:RightOfUseBuildingsMember2020-12-310001760854ifrs-full:GrossCarryingAmountMembernbx:RightOfUseBuildingsMember2021-01-012021-06-300001760854ifrs-full:GrossCarryingAmountMembernbx:RightOfUseBuildingsMember2021-06-300001760854ifrs-full:MachineryMemberifrs-full:GrossCarryingAmountMember2020-12-310001760854ifrs-full:MachineryMemberifrs-full:GrossCarryingAmountMember2021-01-012021-06-300001760854ifrs-full:MachineryMemberifrs-full:GrossCarryingAmountMember2021-06-300001760854ifrs-full:OfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2020-12-310001760854ifrs-full:OfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2021-01-012021-06-300001760854ifrs-full:OfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2021-06-300001760854ifrs-full:GrossCarryingAmountMemberifrs-full:VehiclesMember2020-12-310001760854ifrs-full:GrossCarryingAmountMemberifrs-full:VehiclesMember2021-01-012021-06-300001760854ifrs-full:GrossCarryingAmountMemberifrs-full:VehiclesMember2021-06-300001760854ifrs-full:GrossCarryingAmountMembernbx:RightOfUseTransportEquipmentMember2020-12-310001760854ifrs-full:GrossCarryingAmountMembernbx:RightOfUseTransportEquipmentMember2021-01-012021-06-300001760854ifrs-full:GrossCarryingAmountMembernbx:RightOfUseTransportEquipmentMember2021-06-300001760854ifrs-full:ConstructionInProgressMemberifrs-full:GrossCarryingAmountMember2020-12-310001760854ifrs-full:ConstructionInProgressMemberifrs-full:GrossCarryingAmountMember2021-01-012021-06-300001760854ifrs-full:ConstructionInProgressMemberifrs-full:GrossCarryingAmountMember2021-06-300001760854ifrs-full:FixturesAndFittingsMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2020-12-310001760854ifrs-full:FixturesAndFittingsMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2021-01-012021-06-300001760854ifrs-full:FixturesAndFittingsMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2021-06-300001760854ifrs-full:AccumulatedDepreciationAndAmortisationMembernbx:RightOfUseBuildingsMember2020-12-310001760854ifrs-full:AccumulatedDepreciationAndAmortisationMembernbx:RightOfUseBuildingsMember2021-01-012021-06-300001760854ifrs-full:AccumulatedDepreciationAndAmortisationMembernbx:RightOfUseBuildingsMember2021-06-300001760854ifrs-full:MachineryMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2020-12-310001760854ifrs-full:MachineryMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2021-01-012021-06-300001760854ifrs-full:MachineryMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2021-06-300001760854ifrs-full:OfficeEquipmentMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2020-12-310001760854ifrs-full:OfficeEquipmentMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2021-01-012021-06-300001760854ifrs-full:OfficeEquipmentMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2021-06-300001760854ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:VehiclesMember2020-12-310001760854ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:VehiclesMember2021-01-012021-06-300001760854ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:VehiclesMember2021-06-300001760854ifrs-full:AccumulatedDepreciationAndAmortisationMembernbx:RightOfUseTransportEquipmentMember2020-12-310001760854ifrs-full:AccumulatedDepreciationAndAmortisationMembernbx:RightOfUseTransportEquipmentMember2021-01-012021-06-300001760854ifrs-full:AccumulatedDepreciationAndAmortisationMembernbx:RightOfUseTransportEquipmentMember2021-06-300001760854ifrs-full:FinancialAssetsAtFairValueMembernbx:NonCurrentLiquidityContractMember2019-12-310001760854ifrs-full:FinancialAssetsAtAmortisedCostMembernbx:NonCurrentInvestmentsPledgedAsCollateralMember2019-12-310001760854ifrs-full:FinancialAssetsAtAmortisedCostMembernbx:NonCurrentSecurityDepositMember2019-12-310001760854ifrs-full:FinancialAssetsAtFairValueMembernbx:NonCurrentLiquidityContractMember2020-01-012020-12-310001760854ifrs-full:FinancialAssetsAtAmortisedCostMembernbx:NonCurrentInvestmentsPledgedAsCollateralMember2020-01-012020-12-310001760854ifrs-full:FinancialAssetsAtAmortisedCostMembernbx:NonCurrentSecurityDepositMember2020-01-012020-12-3100017608542020-01-012020-12-310001760854ifrs-full:FinancialAssetsAtFairValueMembernbx:NonCurrentLiquidityContractMember2020-12-310001760854ifrs-full:FinancialAssetsAtAmortisedCostMembernbx:NonCurrentInvestmentsPledgedAsCollateralMember2020-12-310001760854ifrs-full:FinancialAssetsAtAmortisedCostMembernbx:NonCurrentSecurityDepositMember2020-12-310001760854ifrs-full:FinancialAssetsAtFairValueMembernbx:NonCurrentLiquidityContractMember2021-01-012021-06-300001760854ifrs-full:FinancialAssetsAtAmortisedCostMembernbx:NonCurrentInvestmentsPledgedAsCollateralMember2021-01-012021-06-300001760854ifrs-full:FinancialAssetsAtAmortisedCostMembernbx:NonCurrentSecurityDepositMember2021-01-012021-06-300001760854ifrs-full:FinancialAssetsAtFairValueMembernbx:NonCurrentLiquidityContractMember2021-06-300001760854ifrs-full:FinancialAssetsAtAmortisedCostMembernbx:NonCurrentInvestmentsPledgedAsCollateralMember2021-06-300001760854ifrs-full:FinancialAssetsAtAmortisedCostMembernbx:NonCurrentSecurityDepositMember2021-06-300001760854nbx:ResearchAgreementMember2021-06-300001760854nbx:ICONPlcMember2021-06-300001760854nbx:MDAndersonCancerCenterNBTXR3Member2020-12-310001760854nbx:A2021TaxYearMember2021-01-012021-06-300001760854nbx:AGA20181Memberifrs-full:IssuedCapitalMember2021-01-012021-06-300001760854ifrs-full:SharePremiumMembernbx:AGA20181Member2021-01-012021-06-300001760854nbx:AGA20191Memberifrs-full:IssuedCapitalMember2021-01-012021-06-300001760854ifrs-full:SharePremiumMembernbx:AGA20191Member2021-01-012021-06-30nbx:plan_type0001760854nbx:BSA2021AMembernbx:SupervisoryBoardMember2021-04-202021-04-200001760854nbx:BSA2021AMembernbx:SupervisoryBoardMember2021-04-200001760854nbx:SupervisoryBoardMembernbx:BSA2021AInReplacementOfBSA2016Member2021-04-202021-04-200001760854nbx:BSA2021AMembernbx:SupervisoryBoardMember2021-06-302021-06-300001760854nbx:BSA2021BMembernbx:ExternalConsultantMember2021-04-202021-04-200001760854nbx:BSA2021BMembernbx:ExternalConsultantMember2021-04-200001760854nbx:BSA2021BMembernbx:ExternalConsultantMember2021-06-302021-06-300001760854nbx:OSA202104Membernbx:ExecutiveBoardAndEmployeesMember2021-04-202021-04-200001760854nbx:OSA202104OrdinaryMembernbx:ExecutiveBoardAndEmployeesMember2021-04-202021-04-200001760854nbx:OSA202104PerformanceMembernbx:ExecutiveBoardAndEmployeesMember2021-04-202021-04-200001760854nbx:OSA202104Membernbx:ExecutiveBoardAndEmployeesMember2021-04-200001760854nbx:OSAMembernbx:TrancheOneMember2020-11-302020-11-300001760854nbx:TrancheTwoMembernbx:OSAMember2020-11-302020-11-300001760854nbx:OSAMembernbx:TrancheThreeMember2020-11-302020-11-300001760854nbx:TrancheFourMembernbx:OSAMember2020-11-302020-11-300001760854nbx:OSAMember2020-11-302020-11-300001760854nbx:FromFirstYearOfGrantDateMembernbx:OSAMember2020-11-302020-11-300001760854nbx:FromSecondYearOfGrantDateMembernbx:OSAMember2020-11-302020-11-300001760854nbx:OSAMembernbx:FromThirdYearOfGrantDateMember2020-11-302020-11-300001760854nbx:OSA202106PerformanceMembernbx:BartVanRhijnMember2021-06-212021-06-210001760854nbx:OSA202106OrdinaryMembernbx:BartVanRhijnMember2021-06-212021-06-210001760854nbx:OSA202106Membernbx:BartVanRhijnMember2021-06-212021-06-210001760854nbx:OSA202106Membernbx:BartVanRhijnMember2021-06-210001760854nbx:AnneJulietteHermantLaurentLevyAndBartVanRhijnMembernbx:OSAMember2021-06-212021-06-210001760854nbx:AGA2021Membernbx:ExecutiveBoardAndEmployeesMember2021-04-202021-04-200001760854nbx:AGA2021Membernbx:ExecutiveBoardAndEmployeesMember2021-04-200001760854nbx:OSA202104Membernbx:ExecutiveBoardAndEmployeesMembernbx:TrancheOneMember2021-04-202021-04-200001760854nbx:TrancheTwoMembernbx:OSA202104Membernbx:ExecutiveBoardAndEmployeesMember2021-04-202021-04-200001760854nbx:OSA202104Membernbx:ExecutiveBoardAndEmployeesMembernbx:TrancheThreeMember2021-04-202021-04-200001760854nbx:LumpSumRetirementBenefitsMember2020-12-310001760854nbx:LumpSumRetirementBenefitsMember2021-01-012021-06-300001760854nbx:LumpSumRetirementBenefitsMember2021-06-300001760854nbx:NonCurrentOtherProvisionsMember2020-12-310001760854nbx:NonCurrentOtherProvisionsMember2021-01-012021-06-300001760854nbx:NonCurrentOtherProvisionsMember2021-06-300001760854nbx:ProvisionsForDisputesMember2020-12-310001760854nbx:ProvisionsForDisputesMember2021-01-012021-06-300001760854nbx:ProvisionsForDisputesMember2021-06-300001760854nbx:ProvisionsForChargesMember2020-12-310001760854nbx:ProvisionsForChargesMember2021-01-012021-06-300001760854nbx:ProvisionsForChargesMember2021-06-300001760854nbx:CurrentOtherProvisionsMember2020-12-310001760854nbx:CurrentOtherProvisionsMember2021-01-012021-06-300001760854nbx:CurrentOtherProvisionsMember2021-06-300001760854srt:ManagementMember2021-01-012021-06-300001760854nbx:NonManagementMember2021-01-012021-06-300001760854srt:ManagementMember2020-01-012020-12-310001760854nbx:NonManagementMember2020-01-012020-12-310001760854srt:ExecutiveOfficerMember2021-06-300001760854nbx:NonExecutiveMember2021-06-300001760854srt:ExecutiveOfficerMember2020-12-310001760854nbx:NonExecutiveMember2020-12-310001760854ifrs-full:LeaseLiabilitiesMember2021-06-300001760854ifrs-full:LeaseLiabilitiesMember2020-12-310001760854nbx:ConditionalAdvancesMember2021-06-300001760854nbx:ConditionalAdvancesMember2020-12-310001760854nbx:PGELoanAgreementBPIFranceAndHSBCFranceMemberifrs-full:LongtermBorrowingsMember2021-06-300001760854nbx:PGELoanAgreementBPIFranceAndHSBCFranceMemberifrs-full:LongtermBorrowingsMember2020-12-310001760854nbx:EuropeanInvestmentBankLoanAgreementMemberifrs-full:LongtermBorrowingsMember2021-06-300001760854nbx:EuropeanInvestmentBankLoanAgreementMemberifrs-full:LongtermBorrowingsMember2020-12-310001760854nbx:BanquePubliqueDInvestissementMember2018-01-012018-12-310001760854nbx:BanquePubliqueDInvestissementMember2018-12-310001760854nbx:BPIFranceMember2020-06-300001760854nbx:EuropeanInvestmentBankLoanAgreementMemberifrs-full:TopOfRangeMember2018-07-31nbx:tranche0001760854nbx:EuropeanInvestmentBankLoanAgreementMember2018-10-012018-10-310001760854nbx:EuropeanInvestmentBankLoanAgreementMember2019-03-012019-03-310001760854nbx:EuropeanInvestmentBankLoanAgreementMember2020-07-012020-07-310001760854nbx:NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember2020-06-050001760854nbx:NonDilutiveFinancingAgreementHSBCFranceMember2020-06-222020-06-220001760854nbx:NonDilutiveFinancingAgreementHSBCFranceMember2020-06-22nbx:quarterly_instalment0001760854nbx:NonDilutiveFinancingAgreementHSBCFranceMembernbx:TrancheOneMember2020-06-222020-06-220001760854nbx:NonDilutiveFinancingAgreementHSBCFranceMembernbx:TrancheTwoMember2020-06-222020-06-220001760854nbx:NonDilutiveFinancingAgreementBPIFranceMember2020-07-102020-07-100001760854nbx:NonDilutiveFinancingAgreementBPIFranceMember2020-07-100001760854nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMembernbx:BPIFranceAdvanceMember2020-12-310001760854nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMembernbx:InterestFreeBPIFranceLoanMember2020-12-310001760854nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMembernbx:ConditionalAdvanceBPIFranceMember2020-12-310001760854nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMembernbx:EuropeanInvestmentBankLoanAgreementMember2020-12-310001760854nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember2020-12-310001760854nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMembernbx:BPIFranceAdvanceMember2021-01-012021-06-300001760854nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMembernbx:InterestFreeBPIFranceLoanMember2021-01-012021-06-300001760854nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMembernbx:ConditionalAdvanceBPIFranceMember2021-01-012021-06-300001760854nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMembernbx:EuropeanInvestmentBankLoanAgreementMember2021-01-012021-06-300001760854nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember2021-01-012021-06-300001760854nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMembernbx:BPIFranceAdvanceMember2021-06-300001760854nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMembernbx:InterestFreeBPIFranceLoanMember2021-06-300001760854nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMembernbx:ConditionalAdvanceBPIFranceMember2021-06-300001760854nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMembernbx:EuropeanInvestmentBankLoanAgreementMember2021-06-300001760854nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember2021-06-300001760854nbx:NonDilutiveFinancingAgreementHSBCFranceMemberifrs-full:LongtermBorrowingsMember2020-12-310001760854nbx:NonDilutiveFinancingAgreementBPIFranceMemberifrs-full:LongtermBorrowingsMember2020-12-310001760854ifrs-full:LongtermBorrowingsMember2020-12-310001760854nbx:NonDilutiveFinancingAgreementHSBCFranceMemberifrs-full:LongtermBorrowingsMember2021-01-012021-06-300001760854nbx:NonDilutiveFinancingAgreementBPIFranceMemberifrs-full:LongtermBorrowingsMember2021-01-012021-06-300001760854ifrs-full:LongtermBorrowingsMember2021-01-012021-06-300001760854nbx:NonDilutiveFinancingAgreementHSBCFranceMemberifrs-full:LongtermBorrowingsMember2021-06-300001760854nbx:NonDilutiveFinancingAgreementBPIFranceMemberifrs-full:LongtermBorrowingsMember2021-06-300001760854ifrs-full:LongtermBorrowingsMember2021-06-300001760854ifrs-full:LeaseLiabilitiesMember2020-12-310001760854ifrs-full:LeaseLiabilitiesMember2021-01-012021-06-300001760854ifrs-full:LeaseLiabilitiesMember2021-06-300001760854ifrs-full:NotLaterThanOneYearMembernbx:BPIFranceMember2021-06-300001760854nbx:BPIFranceMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2021-06-300001760854ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMembernbx:BPIFranceMember2021-06-300001760854nbx:BPIFranceMemberifrs-full:LaterThanFiveYearsMember2021-06-300001760854nbx:BPIFranceMember2021-06-300001760854ifrs-full:NotLaterThanOneYearMembernbx:InterestFreeLoanBPIFranceMember2021-06-300001760854nbx:InterestFreeLoanBPIFranceMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2021-06-300001760854ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMembernbx:InterestFreeLoanBPIFranceMember2021-06-300001760854nbx:InterestFreeLoanBPIFranceMemberifrs-full:LaterThanFiveYearsMember2021-06-300001760854nbx:InterestFreeLoanBPIFranceMember2021-06-300001760854ifrs-full:NotLaterThanOneYearMembernbx:InterestFreeAdvanceToCuradigmBPIFranceMember2021-06-300001760854ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMembernbx:InterestFreeAdvanceToCuradigmBPIFranceMember2021-06-300001760854ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMembernbx:InterestFreeAdvanceToCuradigmBPIFranceMember2021-06-300001760854ifrs-full:LaterThanFiveYearsMembernbx:InterestFreeAdvanceToCuradigmBPIFranceMember2021-06-300001760854nbx:InterestFreeAdvanceToCuradigmBPIFranceMember2021-06-300001760854nbx:NonDilutiveFinancingAgreementHSBCFranceMemberifrs-full:NotLaterThanOneYearMember2021-06-300001760854nbx:NonDilutiveFinancingAgreementHSBCFranceMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2021-06-300001760854nbx:NonDilutiveFinancingAgreementHSBCFranceMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2021-06-300001760854nbx:NonDilutiveFinancingAgreementHSBCFranceMemberifrs-full:LaterThanFiveYearsMember2021-06-300001760854nbx:NonDilutiveFinancingAgreementHSBCFranceMember2021-06-300001760854nbx:NonDilutiveFinancingAgreementBPIFranceMemberifrs-full:NotLaterThanOneYearMember2021-06-300001760854nbx:NonDilutiveFinancingAgreementBPIFranceMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2021-06-300001760854nbx:NonDilutiveFinancingAgreementBPIFranceMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2021-06-300001760854nbx:NonDilutiveFinancingAgreementBPIFranceMemberifrs-full:LaterThanFiveYearsMember2021-06-300001760854nbx:NonDilutiveFinancingAgreementBPIFranceMember2021-06-300001760854ifrs-full:NotLaterThanOneYearMembernbx:EuropeanInvestmentBankLoanAgreementMember2021-06-300001760854nbx:EuropeanInvestmentBankLoanAgreementMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2021-06-300001760854nbx:EuropeanInvestmentBankLoanAgreementMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2021-06-300001760854nbx:EuropeanInvestmentBankLoanAgreementMemberifrs-full:LaterThanFiveYearsMember2021-06-300001760854nbx:EuropeanInvestmentBankLoanAgreementMember2021-06-300001760854ifrs-full:NotLaterThanOneYearMember2021-06-300001760854ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2021-06-300001760854ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2021-06-300001760854ifrs-full:LaterThanFiveYearsMember2021-06-300001760854nbx:NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember2021-01-012021-06-300001760854nbx:EuropeanInvestmentBankLoanAgreementMemberifrs-full:FixedInterestRateMember2021-06-300001760854ifrs-full:FloatingInterestRateMembernbx:EuropeanInvestmentBankLoanAgreementMember2021-06-300001760854nbx:LianBioNBTXR3Member2021-06-300001760854nbx:NonCurrentFinancialAssetsMember2021-06-300001760854nbx:NonCurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2021-06-300001760854nbx:NonCurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2021-06-300001760854ifrs-full:TradeReceivablesMember2021-06-300001760854ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberifrs-full:TradeReceivablesMember2021-06-300001760854nbx:CashAndCashEquivalentsMember2021-06-300001760854ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembernbx:CashAndCashEquivalentsMember2021-06-300001760854ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2021-06-300001760854ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2021-06-300001760854nbx:NonCurrentFinancialLiabilitiesMember2021-06-300001760854nbx:NonCurrentFinancialLiabilitiesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2021-06-300001760854nbx:CurrentFinancialLiabilitiesMember2021-06-300001760854nbx:CurrentFinancialLiabilitiesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2021-06-300001760854nbx:TradeAndOtherPayablesMember2021-06-300001760854nbx:TradeAndOtherPayablesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2021-06-300001760854ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2021-06-300001760854nbx:EuropeanInvestmentBankLoanAgreementMemberifrs-full:TopOfRangeMember2018-12-310001760854nbx:EuropeanInvestmentBankLoanAgreementMember2018-01-012018-12-310001760854nbx:EuropeanInvestmentBankLoanAgreementMember2018-01-012021-06-300001760854nbx:LianBioNBTXR3Member2021-06-302021-06-3000017608542020-07-012021-06-300001760854nbx:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001760854nbx:SellingGeneralAndAdministrativeExpenseMember2021-01-012021-06-30nbx:employee0001760854nbx:ResearchAndDevelopmentExpenseMember2021-06-300001760854nbx:SellingGeneralAndAdministrativeExpenseMember2021-06-300001760854nbx:ResearchAndDevelopmentExpenseMember2020-01-012020-06-300001760854nbx:SellingGeneralAndAdministrativeExpenseMember2020-01-012020-06-300001760854nbx:BSPCE20122Member2012-12-182012-12-180001760854nbx:BSPCE082013Member2013-08-282013-08-280001760854nbx:BSPCE092014Member2014-09-162014-09-160001760854nbx:BSPCE20151Member2015-02-102015-02-100001760854nbx:BSPCE20153Member2015-06-102015-06-100001760854nbx:BSPCE20122Membernbx:CorporateOfficersMember2012-12-182012-12-180001760854nbx:BSPCE082013Membernbx:CorporateOfficersMember2013-08-282013-08-280001760854nbx:CorporateOfficersMembernbx:BSPCE092014Member2014-09-162014-09-160001760854nbx:BSPCE20151Membernbx:CorporateOfficersMember2015-02-102015-02-100001760854nbx:BSPCE20153Membernbx:CorporateOfficersMember2015-06-102015-06-100001760854nbx:BSPCE20122Membernbx:LaurentLevyMember2012-12-182012-12-180001760854nbx:BSPCE082013Membernbx:LaurentLevyMember2013-08-282013-08-280001760854nbx:LaurentLevyMembernbx:BSPCE092014Member2014-09-162014-09-160001760854nbx:BSPCE20151Membernbx:LaurentLevyMember2015-02-102015-02-100001760854nbx:BSPCE20153Membernbx:LaurentLevyMember2015-06-102015-06-100001760854nbx:BSPCE20122Membernbx:BeneficiariesOtherThanCorporateOfficersMember2012-12-182012-12-180001760854nbx:BSPCE082013Membernbx:BeneficiariesOtherThanCorporateOfficersMember2013-08-282013-08-280001760854nbx:BeneficiariesOtherThanCorporateOfficersMembernbx:BSPCE092014Member2014-09-162014-09-160001760854nbx:BSPCE20151Membernbx:BeneficiariesOtherThanCorporateOfficersMember2015-02-102015-02-100001760854nbx:BSPCE20153Membernbx:BeneficiariesOtherThanCorporateOfficersMember2015-06-102015-06-100001760854nbx:BSPCE20122Member2021-06-302021-06-300001760854nbx:BSPCE082013Member2021-06-302021-06-300001760854nbx:BSPCE092014Member2021-06-302021-06-300001760854nbx:BSPCE20151Member2021-06-302021-06-300001760854nbx:BSPCE20153Member2021-06-302021-06-300001760854nbx:BSPCE20122Member2021-06-300001760854nbx:BSPCE082013Member2021-06-300001760854nbx:BSPCE092014Member2021-06-300001760854nbx:BSPCE20151Member2021-06-300001760854nbx:BSPCE20153Member2021-06-300001760854nbx:BSPCE2016OrdinaryMember2016-02-022016-02-020001760854nbx:BSPCE2016PerformanceMember2016-02-022016-02-020001760854nbx:BSPCE2017OrdinaryMember2017-01-072017-01-070001760854nbx:BSPCE2017Member2017-01-072017-01-070001760854nbx:BSPCE2016OrdinaryMembernbx:CorporateOfficersMember2016-02-022016-02-020001760854nbx:BSPCE2016PerformanceMembernbx:CorporateOfficersMember2016-02-022016-02-020001760854nbx:BSPCE2017OrdinaryMembernbx:CorporateOfficersMember2017-01-072017-01-070001760854nbx:BSPCE2017Membernbx:CorporateOfficersMember2017-01-072017-01-070001760854nbx:BSPCE2016OrdinaryMembernbx:LaurentLevyMember2016-02-022016-02-020001760854nbx:BSPCE2016PerformanceMembernbx:LaurentLevyMember2016-02-022016-02-020001760854nbx:LaurentLevyMembernbx:BSPCE2017OrdinaryMember2017-01-072017-01-070001760854nbx:BSPCE2017Membernbx:LaurentLevyMember2017-01-072017-01-070001760854nbx:BSPCE2016OrdinaryMembernbx:BeneficiariesOtherThanCorporateOfficersMember2016-02-022016-02-020001760854nbx:BSPCE2016PerformanceMembernbx:BeneficiariesOtherThanCorporateOfficersMember2016-02-022016-02-020001760854nbx:BeneficiariesOtherThanCorporateOfficersMembernbx:BSPCE2017OrdinaryMember2017-01-072017-01-070001760854nbx:BSPCE2017Membernbx:BeneficiariesOtherThanCorporateOfficersMember2017-01-072017-01-070001760854nbx:BSPCE2016OrdinaryMember2021-06-302021-06-300001760854nbx:BSPCE2016PerformanceMember2021-06-302021-06-300001760854nbx:BSPCE2017OrdinaryMember2021-06-302021-06-300001760854nbx:BSPCE2017Member2021-06-302021-06-300001760854nbx:BSPCE2016OrdinaryMember2021-06-300001760854nbx:BSPCE2016PerformanceMember2021-06-300001760854nbx:BSPCE2017OrdinaryMember2021-06-300001760854nbx:BSPCE2017Member2021-06-300001760854nbx:BSA0412Member2012-05-042012-05-040001760854nbx:BSA2013Member2013-04-102013-04-100001760854nbx:BSA2014Member2014-09-162014-09-160001760854nbx:BSA20151Member2015-02-102015-02-100001760854nbx:BSA20152AMember2015-06-252015-06-250001760854nbx:BSA20162Member2016-11-032016-11-030001760854nbx:BSA2017Member2017-01-072017-01-070001760854nbx:BSA0412Membernbx:CorporateOfficersMember2012-05-042012-05-040001760854nbx:CorporateOfficersMembernbx:BSA2013Member2013-04-102013-04-100001760854nbx:BSA2014Membernbx:CorporateOfficersMember2014-09-162014-09-160001760854nbx:BSA20151Membernbx:CorporateOfficersMember2015-02-102015-02-100001760854nbx:BSA20152AMembernbx:CorporateOfficersMember2015-06-252015-06-250001760854nbx:BSA20162Membernbx:CorporateOfficersMember2016-11-032016-11-030001760854nbx:CorporateOfficersMembernbx:BSA2017Member2017-01-072017-01-070001760854nbx:AnneMarieGraffinMembernbx:BSA20151Member2015-02-102015-02-100001760854nbx:AnneMarieGraffinMembernbx:BSA2017Member2017-01-072017-01-070001760854nbx:EnnoSpillnerMembernbx:BSA20151Member2015-02-102015-02-100001760854nbx:EnnoSpillnerMembernbx:BSA2017Member2017-01-072017-01-070001760854nbx:AlainHerreraMembernbx:BSA2014Member2014-09-162014-09-160001760854nbx:AlainHerreraMembernbx:BSA20151Member2015-02-102015-02-100001760854nbx:AlainHerreraMembernbx:BSA2017Member2017-01-072017-01-070001760854nbx:BSA0412Membernbx:ChristopheDouatMember2012-05-042012-05-040001760854nbx:BSA2014Membernbx:ChristopheDouatMember2014-09-162014-09-160001760854nbx:ChristopheDouatMembernbx:BSA20151Member2015-02-102015-02-100001760854nbx:ChristopheDouatMembernbx:BSA2017Member2017-01-072017-01-070001760854nbx:BSA0412Membernbx:BeneficiariesOtherThanCorporateOfficersMember2012-05-042012-05-040001760854nbx:BeneficiariesOtherThanCorporateOfficersMembernbx:BSA2013Member2013-04-102013-04-100001760854nbx:BSA2014Membernbx:BeneficiariesOtherThanCorporateOfficersMember2014-09-162014-09-160001760854nbx:BeneficiariesOtherThanCorporateOfficersMembernbx:BSA20151Member2015-02-102015-02-100001760854nbx:BSA20152AMembernbx:BeneficiariesOtherThanCorporateOfficersMember2015-06-252015-06-250001760854nbx:BSA20162Membernbx:BeneficiariesOtherThanCorporateOfficersMember2016-11-032016-11-030001760854nbx:BeneficiariesOtherThanCorporateOfficersMembernbx:BSA2017Member2017-01-072017-01-070001760854nbx:BSA0412Member2021-06-302021-06-300001760854nbx:BSA2013Member2021-06-302021-06-300001760854nbx:BSA2014Member2021-06-302021-06-300001760854nbx:BSA20151Member2021-06-302021-06-300001760854nbx:BSA20152AMember2021-06-302021-06-300001760854nbx:BSA20162Member2021-06-302021-06-300001760854nbx:BSA2017Member2021-06-302021-06-300001760854nbx:BSA0412Member2021-06-300001760854nbx:BSA2013Member2021-06-300001760854nbx:BSA2014Member2021-06-300001760854nbx:BSA20151Member2021-06-300001760854nbx:BSA20152AMember2021-06-300001760854nbx:BSA20162Member2021-06-300001760854nbx:BSA2017Member2021-06-300001760854nbx:BSA2018Member2018-03-062018-03-060001760854nbx:BSA20181Member2018-03-062018-03-060001760854nbx:BSA20182Member2018-07-272018-07-270001760854nbx:BSA20191Member2019-03-292019-03-290001760854nbx:BSA2020Member2020-03-172020-03-170001760854nbx:BSA2021AMember2021-04-202021-04-200001760854nbx:BSA2021BMember2021-04-202021-04-200001760854nbx:BSA2018Membernbx:CorporateOfficersMember2018-03-062018-03-060001760854nbx:BSA20181Membernbx:CorporateOfficersMember2018-03-062018-03-060001760854nbx:BSA20182Membernbx:CorporateOfficersMember2018-07-272018-07-270001760854nbx:BSA20191Membernbx:CorporateOfficersMember2019-03-292019-03-290001760854nbx:BSA2020Membernbx:CorporateOfficersMember2020-03-172020-03-170001760854nbx:BSA2021AMembernbx:CorporateOfficersMember2021-04-202021-04-200001760854nbx:BSA2021BMembernbx:CorporateOfficersMember2021-04-202021-04-200001760854nbx:BSA2018Membernbx:AnneMarieGraffinMember2018-03-062018-03-060001760854nbx:BSA20191Membernbx:AnneMarieGraffinMember2019-03-292019-03-290001760854nbx:BSA2020Membernbx:AnneMarieGraffinMember2020-03-172020-03-170001760854nbx:BSA2021AMembernbx:AnneMarieGraffinMember2021-04-202021-04-200001760854nbx:BSA2018Membernbx:EnnoSpillnerMember2018-03-062018-03-060001760854nbx:BSA20191Membernbx:EnnoSpillnerMember2019-03-292019-03-290001760854nbx:BSA2020Membernbx:EnnoSpillnerMember2020-03-172020-03-170001760854nbx:BSA2021AMembernbx:EnnoSpillnerMember2021-04-202021-04-200001760854nbx:BSA2018Membernbx:AlainHerreraMember2018-03-062018-03-060001760854nbx:AlainHerreraMembernbx:BSA20191Member2019-03-292019-03-290001760854nbx:AlainHerreraMembernbx:BSA2020Member2020-03-172020-03-170001760854nbx:BSA2021AMembernbx:AlainHerreraMember2021-04-202021-04-200001760854nbx:BSA2018Membernbx:ChristopheDouatMember2018-03-062018-03-060001760854nbx:BSA20191Membernbx:ChristopheDouatMember2019-03-292019-03-290001760854nbx:BSA2020Membernbx:ChristopheDouatMember2020-03-172020-03-170001760854nbx:BSA2021AMembernbx:ChristopheDouatMember2021-04-202021-04-200001760854nbx:BSA2018Membernbx:BeneficiariesOtherThanCorporateOfficersMember2018-03-062018-03-060001760854nbx:BeneficiariesOtherThanCorporateOfficersMembernbx:BSA20181Member2018-03-062018-03-060001760854nbx:BSA20182Membernbx:BeneficiariesOtherThanCorporateOfficersMember2018-07-272018-07-270001760854nbx:BSA20191Membernbx:BeneficiariesOtherThanCorporateOfficersMember2019-03-292019-03-290001760854nbx:BSA2020Membernbx:BeneficiariesOtherThanCorporateOfficersMember2020-03-172020-03-170001760854nbx:BSA2021AMembernbx:BeneficiariesOtherThanCorporateOfficersMember2021-04-202021-04-200001760854nbx:BSA2021BMembernbx:BeneficiariesOtherThanCorporateOfficersMember2021-04-202021-04-200001760854nbx:BSA2018Member2021-06-302021-06-300001760854nbx:BSA20181Member2021-06-302021-06-300001760854nbx:BSA20182Member2021-06-302021-06-300001760854nbx:BSA20191Member2021-06-302021-06-300001760854nbx:BSA2020Member2021-06-302021-06-300001760854nbx:BSA2021AMember2021-06-302021-06-300001760854nbx:BSA2021BMember2021-06-302021-06-300001760854nbx:BSA2018Member2021-06-300001760854nbx:BSA20181Member2021-06-300001760854nbx:BSA20182Member2021-06-300001760854nbx:BSA20191Member2021-06-300001760854nbx:BSA2020Member2021-06-300001760854nbx:BSA2021AMember2021-06-300001760854nbx:BSA2021BMember2021-06-300001760854nbx:OSA20161PerformanceMember2016-02-022016-02-020001760854nbx:OSA20162Member2016-11-032016-11-030001760854nbx:OSA2017OrdinaryMember2017-01-072017-01-070001760854nbx:OSA2018Member2018-03-062018-03-060001760854nbx:OSA20191Member2019-03-292019-03-290001760854nbx:OSALLY2019Member2019-10-242019-10-240001760854nbx:CorporateOfficersMembernbx:OSA20161PerformanceMember2016-02-022016-02-020001760854nbx:OSA20162Membernbx:CorporateOfficersMember2016-11-032016-11-030001760854nbx:OSA2017OrdinaryMembernbx:CorporateOfficersMember2017-01-072017-01-070001760854nbx:CorporateOfficersMembernbx:OSA2018Member2018-03-062018-03-060001760854nbx:OSA20191Membernbx:CorporateOfficersMember2019-03-292019-03-290001760854nbx:OSALLY2019Membernbx:CorporateOfficersMember2019-10-242019-10-240001760854nbx:LaurentLevyMembernbx:OSALLY2019Member2019-10-242019-10-240001760854nbx:BeneficiariesOtherThanCorporateOfficersMembernbx:OSA20161PerformanceMember2016-02-022016-02-020001760854nbx:OSA20162Membernbx:BeneficiariesOtherThanCorporateOfficersMember2016-11-032016-11-030001760854nbx:OSA2017OrdinaryMembernbx:BeneficiariesOtherThanCorporateOfficersMember2017-01-072017-01-070001760854nbx:BeneficiariesOtherThanCorporateOfficersMembernbx:OSA2018Member2018-03-062018-03-060001760854nbx:OSA20191Membernbx:BeneficiariesOtherThanCorporateOfficersMember2019-03-292019-03-290001760854nbx:BeneficiariesOtherThanCorporateOfficersMembernbx:OSALLY2019Member2019-10-242019-10-240001760854nbx:OSA20161PerformanceMember2021-06-302021-06-300001760854nbx:OSA20162Member2021-06-302021-06-300001760854nbx:OSA2017OrdinaryMember2021-06-302021-06-300001760854nbx:OSA2018Member2021-06-302021-06-300001760854nbx:OSA20191Member2021-06-302021-06-300001760854nbx:OSALLY2019Member2021-06-302021-06-300001760854nbx:OSA20161PerformanceMember2021-06-300001760854nbx:OSA20162Member2021-06-300001760854nbx:OSA2017OrdinaryMember2021-06-300001760854nbx:OSA2018Member2021-06-300001760854nbx:OSA20191Member2021-06-300001760854nbx:OSALLY2019Member2021-06-300001760854nbx:OSA2020Member2020-03-112020-03-110001760854nbx:OSA202104OrdinaryMember2021-04-202021-04-200001760854nbx:OSA202104PerformanceMember2021-04-202021-04-200001760854nbx:OSA202106PerformanceMember2021-06-212021-06-210001760854nbx:OSA202106OrdinaryMember2021-06-212021-06-210001760854nbx:CorporateOfficersMembernbx:OSA2020Member2020-03-112020-03-110001760854nbx:OSA202104OrdinaryMembernbx:CorporateOfficersMember2021-04-202021-04-200001760854nbx:OSA202104PerformanceMembernbx:CorporateOfficersMember2021-04-202021-04-200001760854nbx:OSA202106PerformanceMembernbx:CorporateOfficersMember2021-06-212021-06-210001760854nbx:OSA202106OrdinaryMembernbx:CorporateOfficersMember2021-06-212021-06-210001760854nbx:LaurentLevyMembernbx:OSA2020Member2020-03-112020-03-110001760854nbx:OSA202104PerformanceMembernbx:LaurentLevyMember2021-04-202021-04-200001760854nbx:AnneJulietteHermantMembernbx:OSA2020Member2020-03-112020-03-110001760854nbx:OSA202104PerformanceMembernbx:AnneJulietteHermantMember2021-04-202021-04-200001760854nbx:BeneficiariesOtherThanCorporateOfficersMembernbx:OSA2020Member2020-03-112020-03-110001760854nbx:OSA202104OrdinaryMembernbx:BeneficiariesOtherThanCorporateOfficersMember2021-04-202021-04-200001760854nbx:OSA202104PerformanceMembernbx:BeneficiariesOtherThanCorporateOfficersMember2021-04-202021-04-200001760854nbx:BeneficiariesOtherThanCorporateOfficersMembernbx:OSA202106PerformanceMember2021-06-212021-06-210001760854nbx:OSA202106OrdinaryMembernbx:BeneficiariesOtherThanCorporateOfficersMember2021-06-212021-06-210001760854nbx:OSA2020Member2021-06-302021-06-300001760854nbx:OSA202104OrdinaryMember2021-06-302021-06-300001760854nbx:OSA202104PerformanceMember2021-06-302021-06-300001760854nbx:OSA202106PerformanceMember2021-06-302021-06-300001760854nbx:OSA202106OrdinaryMember2021-06-302021-06-300001760854nbx:OSA2020Member2021-06-300001760854nbx:OSA202104OrdinaryMember2021-06-300001760854nbx:OSA202104PerformanceMember2021-06-300001760854nbx:OSA202106PerformanceMember2021-06-300001760854nbx:OSA202106OrdinaryMember2021-06-300001760854nbx:AGA20181Member2018-03-062018-03-060001760854nbx:AGA20182Member2018-07-272018-07-270001760854nbx:AGA20191Member2019-03-292019-03-290001760854nbx:AGA2020Member2020-03-112020-03-110001760854nbx:AGA2021Member2021-04-202021-04-200001760854nbx:AGA20181Membernbx:CorporateOfficersMember2018-03-062018-03-060001760854nbx:AGA20182Membernbx:CorporateOfficersMember2018-07-272018-07-270001760854nbx:AGA20191Membernbx:CorporateOfficersMember2019-03-292019-03-290001760854nbx:AGA2020Membernbx:CorporateOfficersMember2020-03-112020-03-110001760854nbx:AGA2021Membernbx:CorporateOfficersMember2021-04-202021-04-200001760854nbx:AGA20181Membernbx:LaurentLevyMember2018-03-062018-03-060001760854nbx:AGA20182Membernbx:LaurentLevyMember2018-07-272018-07-270001760854nbx:AGA20191Membernbx:LaurentLevyMember2019-03-292019-03-290001760854nbx:AGA2020Membernbx:LaurentLevyMember2020-03-112020-03-110001760854nbx:LaurentLevyMembernbx:AGA2021Member2021-04-202021-04-200001760854nbx:AnneJulietteHermantMembernbx:AGA20181Member2018-03-062018-03-060001760854nbx:AGA20182Membernbx:AnneJulietteHermantMember2018-07-272018-07-270001760854nbx:AGA20191Membernbx:AnneJulietteHermantMember2019-03-292019-03-290001760854nbx:AnneJulietteHermantMembernbx:AGA2020Member2020-03-112020-03-110001760854nbx:AnneJulietteHermantMembernbx:AGA2021Member2021-04-202021-04-200001760854nbx:BeneficiariesOtherThanCorporateOfficersMembernbx:AGA20181Member2018-03-062018-03-060001760854nbx:AGA20182Membernbx:BeneficiariesOtherThanCorporateOfficersMember2018-07-272018-07-270001760854nbx:AGA20191Membernbx:BeneficiariesOtherThanCorporateOfficersMember2019-03-292019-03-290001760854nbx:BeneficiariesOtherThanCorporateOfficersMembernbx:AGA2020Member2020-03-112020-03-110001760854nbx:BeneficiariesOtherThanCorporateOfficersMembernbx:AGA2021Member2021-04-202021-04-200001760854nbx:AGA20181Member2021-06-302021-06-300001760854nbx:AGA20182Member2021-06-302021-06-300001760854nbx:AGA20191Member2021-06-302021-06-300001760854nbx:AGA2020Member2021-06-302021-06-300001760854nbx:AGA2021Member2021-06-302021-06-300001760854nbx:AGA20181Member2021-06-300001760854nbx:AGA20182Member2021-06-300001760854nbx:AGA20191Member2021-06-300001760854nbx:AGA2020Member2021-06-300001760854nbx:AGA2021Member2021-06-300001760854nbx:AGA20181Membernbx:FrenchTaxResidentsMember2018-03-062018-03-060001760854nbx:AGA20191Membernbx:FrenchTaxResidentsMember2019-03-292019-03-290001760854nbx:BSPCEMember2021-06-300001760854nbx:BSAMember2021-06-300001760854nbx:OSAMember2021-06-300001760854nbx:AGAMember2021-06-300001760854nbx:BSA2014Member2021-01-012021-06-300001760854nbx:BSPCE20121Member2012-05-042012-05-040001760854nbx:BSPCE20121Member2021-01-012021-06-300001760854nbx:BSPCE20121Member2020-01-012020-06-300001760854nbx:BSPCE20122Membernbx:TrancheOneMember2012-12-182012-12-180001760854nbx:BSPCE20122Membernbx:TrancheTwoMember2012-12-182012-12-180001760854nbx:BSPCE20122Membernbx:TrancheOneMember2012-12-182012-12-180001760854nbx:BSPCE20122Membernbx:TrancheTwoMember2012-12-182012-12-180001760854nbx:BSPCE20122Member2021-01-012021-06-300001760854nbx:BSPCE20122Member2020-01-012020-06-300001760854nbx:BSPCE042013Member2013-04-102013-04-100001760854nbx:BSPCE042013Member2021-01-012021-06-300001760854nbx:BSPCE042013Member2020-01-012020-06-300001760854nbx:BSPCE082013Member2021-01-012021-06-300001760854nbx:BSPCE082013Member2020-01-012020-06-300001760854nbx:TrancheOneMembernbx:BSPCE092014Member2014-09-162014-09-160001760854nbx:TrancheTwoMembernbx:BSPCE092014Member2014-09-162014-09-160001760854nbx:TrancheThreeMembernbx:BSPCE092014Member2014-09-162014-09-160001760854nbx:BSPCE092014Member2021-01-012021-06-300001760854nbx:BSPCE092014Member2020-01-012020-06-300001760854nbx:BSPCE20152Member2015-02-102015-02-100001760854nbx:TrancheOneMembernbx:BSPCE20152Member2015-02-102015-02-100001760854nbx:TrancheTwoMembernbx:BSPCE20152Member2015-02-102015-02-100001760854nbx:TrancheThreeMembernbx:BSPCE20152Member2015-02-102015-02-100001760854nbx:TrancheOneMembernbx:BSPCE20152Member2015-02-102015-02-100001760854nbx:TrancheTwoMembernbx:BSPCE20152Member2015-02-102015-02-100001760854nbx:TrancheThreeMembernbx:BSPCE20152Member2015-02-102015-02-100001760854nbx:BSPCE20152Member2021-01-012021-06-300001760854nbx:BSPCE20152Member2020-01-012020-06-300001760854nbx:BSPCE20153Membernbx:TrancheOneMember2015-06-102015-06-100001760854nbx:BSPCE20153Membernbx:TrancheTwoMember2015-06-102015-06-100001760854nbx:BSPCE20153Membernbx:TrancheThreeMember2015-06-102015-06-100001760854nbx:BSPCE20153Membernbx:TrancheOneMember2015-06-102015-06-100001760854nbx:BSPCE20153Membernbx:TrancheTwoMember2015-06-102015-06-100001760854nbx:BSPCE20153Membernbx:TrancheThreeMember2015-06-102015-06-100001760854nbx:BSPCE20153Member2021-01-012021-06-300001760854nbx:BSPCE20153Member2020-01-012020-06-300001760854nbx:BSPCE2016OrdinaryMembernbx:TrancheOneMember2016-02-022016-02-020001760854nbx:BSPCE2016OrdinaryMembernbx:TrancheTwoMember2016-02-022016-02-020001760854nbx:BSPCE2016OrdinaryMembernbx:TrancheThreeMember2016-02-022016-02-020001760854nbx:BSPCE2016OrdinaryMembernbx:TrancheOneMember2016-02-022016-02-020001760854nbx:BSPCE2016OrdinaryMembernbx:TrancheTwoMember2016-02-022016-02-020001760854nbx:BSPCE2016OrdinaryMembernbx:TrancheThreeMember2016-02-022016-02-020001760854nbx:BSPCE2016OrdinaryMember2021-01-012021-06-300001760854nbx:BSPCE2016OrdinaryMember2020-01-012020-06-300001760854nbx:BSPCE2016PerformanceMember2021-01-012021-06-300001760854nbx:BSPCE2016PerformanceMember2020-01-012020-06-300001760854nbx:BSPCE2017OrdinaryMembernbx:TrancheOneMember2017-01-072017-01-070001760854nbx:TrancheTwoMembernbx:BSPCE2017OrdinaryMember2017-01-072017-01-070001760854nbx:BSPCE2017OrdinaryMembernbx:TrancheThreeMember2017-01-072017-01-070001760854nbx:BSPCE2017OrdinaryMembernbx:TrancheOneMember2017-01-072017-01-070001760854nbx:TrancheTwoMembernbx:BSPCE2017OrdinaryMember2017-01-072017-01-070001760854nbx:TrancheThreeMembernbx:BSPCE2017OrdinaryMember2017-01-072017-01-070001760854nbx:BSPCE2017OrdinaryMember2021-01-012021-06-300001760854nbx:BSPCE2017OrdinaryMember2020-01-012020-06-300001760854nbx:BSPCE2017PerformanceMember2017-01-072017-01-070001760854nbx:BSPCE2017PerformanceMember2021-01-012021-06-300001760854nbx:BSPCE2017PerformanceMember2020-01-012020-06-300001760854nbx:BSPCE2017Member2021-01-012021-06-300001760854nbx:BSPCE2017Member2020-01-012020-06-300001760854nbx:BSPCE2017ProjectMember2017-01-072017-01-070001760854nbx:BSPCE2017ProjectMember2021-01-012021-06-300001760854nbx:BSPCE2017ProjectMember2020-01-012020-06-300001760854nbx:BSPCEMember2021-01-012021-06-300001760854nbx:BSPCEMember2020-01-012020-06-300001760854nbx:BSA0412Member2021-01-012021-06-300001760854nbx:BSA0412Member2020-01-012020-06-300001760854nbx:BSA2013Member2021-01-012021-06-300001760854nbx:BSA2013Member2020-01-012020-06-300001760854nbx:BSA2014Member2020-01-012020-06-300001760854nbx:TrancheOneMembernbx:BSA20151Member2015-02-102015-02-100001760854nbx:TrancheTwoMembernbx:BSA20151Member2015-02-102015-02-100001760854nbx:BSA20151Member2021-01-012021-06-300001760854nbx:BSA20151Member2020-01-012020-06-300001760854nbx:BSA20152AMembernbx:TrancheOneMember2015-06-252015-06-250001760854nbx:BSA20152AMembernbx:TrancheTwoMember2015-06-252015-06-250001760854nbx:BSA20152AMembernbx:TrancheThreeMember2015-06-252015-06-250001760854nbx:BSA20152AMembernbx:TrancheFourMember2015-06-252015-06-250001760854nbx:BSA20152AMembernbx:TrancheOneMember2015-06-252015-06-250001760854nbx:BSA20152AMembernbx:TrancheTwoMember2015-06-252015-06-250001760854nbx:BSA20152AMembernbx:TrancheThreeMember2015-06-252015-06-250001760854nbx:BSA20152AMembernbx:TrancheFourMember2015-06-252015-06-250001760854nbx:BSA20152AMember2021-01-012021-06-300001760854nbx:BSA20152AMember2020-01-012020-06-300001760854nbx:BSA20152BMember2015-06-252015-06-250001760854nbx:TrancheOneMembernbx:BSA20152BMember2015-06-252015-06-250001760854nbx:TrancheTwoMembernbx:BSA20152BMember2015-06-252015-06-250001760854nbx:BSA20152BMembernbx:TrancheOneMember2015-06-252015-06-250001760854nbx:TrancheTwoMembernbx:BSA20152BMember2015-06-252015-06-250001760854nbx:BSA20152BMember2021-01-012021-06-300001760854nbx:BSA20152BMember2020-01-012020-06-300001760854nbx:BSA2016OrdinaryMember2016-02-022016-02-020001760854nbx:BSA2016OrdinaryMember2021-01-012021-06-300001760854nbx:BSA2016OrdinaryMember2020-01-012020-06-300001760854nbx:BSA2016PerformanceMember2016-02-022016-02-020001760854nbx:BSA2016PerformanceMember2021-01-012021-06-300001760854nbx:BSA2016PerformanceMember2020-01-012020-06-300001760854nbx:BSA20162Member2021-01-012021-06-300001760854nbx:BSA20162Member2020-01-012020-06-300001760854nbx:BSA2017Member2021-01-012021-06-300001760854nbx:BSA2017Member2020-01-012020-06-300001760854nbx:BSA2018Membernbx:TrancheOneMember2018-03-062018-03-060001760854nbx:BSA2018Membernbx:TrancheTwoMember2018-03-062018-03-060001760854nbx:BSA2018Member2021-01-012021-06-300001760854nbx:BSA2018Member2020-01-012020-06-300001760854nbx:BSA20181Membernbx:TrancheOneMember2018-03-062018-03-060001760854nbx:TrancheTwoMembernbx:BSA20181Member2018-03-062018-03-060001760854nbx:BSA20181Member2021-01-012021-06-300001760854nbx:BSA20181Member2020-01-012020-06-300001760854nbx:BSA20182Membernbx:TrancheOneMember2018-07-272018-07-270001760854nbx:BSA20182Membernbx:TrancheTwoMember2018-07-272018-07-270001760854nbx:BSA20182Member2021-01-012021-06-300001760854nbx:BSA20182Member2020-01-012020-06-300001760854nbx:BSA20191Membernbx:TrancheOneMember2019-03-292019-03-290001760854nbx:BSA20191Membernbx:TrancheTwoMember2019-03-292019-03-290001760854nbx:BSA20191Membernbx:TrancheOneMember2019-03-292019-03-290001760854nbx:BSA20191Membernbx:TrancheTwoMember2019-03-292019-03-290001760854nbx:BSA20191Member2021-01-012021-06-300001760854nbx:BSA20191Member2020-01-012020-06-300001760854nbx:BSA2020Member2021-01-012021-06-300001760854nbx:BSA2020Member2020-01-012020-06-300001760854nbx:BSA2021AMember2021-01-012021-06-300001760854nbx:BSA2021AMember2020-01-012020-06-300001760854nbx:BSA2021BMember2021-01-012021-06-300001760854nbx:BSA2021BMember2020-01-012020-06-300001760854nbx:BSAMember2021-01-012021-06-300001760854nbx:BSAMember2020-01-012020-06-300001760854nbx:OSA20161OrdinaryMember2016-02-022016-02-020001760854nbx:OSA20161OrdinaryMembernbx:TrancheOneMember2016-02-022016-02-020001760854nbx:OSA20161OrdinaryMembernbx:TrancheTwoMember2016-02-022016-02-020001760854nbx:OSA20161OrdinaryMembernbx:TrancheThreeMember2016-02-022016-02-02nbx:uSDollarPerEuro0001760854nbx:OSA20161OrdinaryMembernbx:TrancheOneMember2016-02-022016-02-020001760854nbx:OSA20161OrdinaryMembernbx:TrancheTwoMember2016-02-022016-02-020001760854nbx:OSA20161OrdinaryMembernbx:TrancheThreeMember2016-02-022016-02-020001760854nbx:OSA20161OrdinaryMember2021-01-012021-06-300001760854nbx:OSA20161OrdinaryMember2020-01-012020-06-300001760854nbx:OSA20161PerformanceMember2021-01-012021-06-300001760854nbx:OSA20161PerformanceMember2020-01-012020-06-300001760854nbx:OSA20162Membernbx:TrancheOneMember2016-11-032016-11-030001760854nbx:OSA20162Membernbx:TrancheTwoMember2016-11-032016-11-030001760854nbx:OSA20162Membernbx:TrancheThreeMember2016-11-032016-11-030001760854nbx:OSA20162Membernbx:TrancheOneMember2016-11-032016-11-030001760854nbx:OSA20162Membernbx:TrancheTwoMember2016-11-032016-11-030001760854nbx:OSA20162Membernbx:TrancheThreeMember2016-11-032016-11-030001760854nbx:OSA20162Member2021-01-012021-06-300001760854nbx:OSA20162Member2020-01-012020-06-300001760854nbx:OSA2017OrdinaryMembernbx:TrancheOneMember2017-01-072017-01-070001760854nbx:OSA2017OrdinaryMembernbx:TrancheTwoMember2017-01-072017-01-070001760854nbx:OSA2017OrdinaryMembernbx:TrancheThreeMember2017-01-072017-01-070001760854nbx:OSA2017OrdinaryMembernbx:TrancheOneMember2017-01-072017-01-070001760854nbx:OSA2017OrdinaryMembernbx:TrancheTwoMember2017-01-072017-01-070001760854nbx:OSA2017OrdinaryMembernbx:TrancheThreeMember2017-01-072017-01-070001760854nbx:OSA2017OrdinaryMember2021-01-012021-06-300001760854nbx:OSA2017OrdinaryMember2020-01-012020-06-300001760854nbx:OSA2017PerformanceMember2017-01-072017-01-070001760854nbx:OSA2017PerformanceMember2021-01-012021-06-300001760854nbx:OSA2017PerformanceMember2020-01-012020-06-300001760854nbx:TrancheOneMembernbx:OSA2018Member2018-03-062018-03-060001760854nbx:TrancheTwoMembernbx:OSA2018Member2018-03-062018-03-060001760854nbx:TrancheThreeMembernbx:OSA2018Member2018-03-062018-03-060001760854nbx:OSA2018Member2021-01-012021-06-300001760854nbx:OSA2018Member2020-01-012020-06-300001760854nbx:OSA20191Membernbx:TrancheOneMember2019-03-292019-03-290001760854nbx:OSA20191Membernbx:TrancheTwoMember2019-03-292019-03-290001760854nbx:OSA20191Membernbx:TrancheOneMember2019-03-292019-03-290001760854nbx:OSA20191Membernbx:TrancheTwoMember2019-03-292019-03-290001760854nbx:OSA20191Member2021-01-012021-06-300001760854nbx:OSA20191Member2020-01-012020-06-300001760854nbx:OSA20192Member2019-10-242019-10-240001760854nbx:OSA20192Member2021-01-012021-06-300001760854nbx:OSA20192Member2020-01-012020-06-300001760854nbx:OSA2020Member2021-01-012021-06-300001760854nbx:OSA2020Member2020-01-012020-06-300001760854nbx:OSA202104OrdinaryMembernbx:TrancheOneMember2021-04-202021-04-200001760854nbx:OSA202104OrdinaryMembernbx:TrancheTwoMember2021-04-202021-04-200001760854nbx:OSA202104OrdinaryMembernbx:TrancheThreeMember2021-04-202021-04-200001760854nbx:OSA202104OrdinaryMembernbx:TrancheOneMember2021-04-202021-04-200001760854nbx:OSA202104OrdinaryMembernbx:TrancheTwoMember2021-04-202021-04-200001760854nbx:OSA202104OrdinaryMembernbx:TrancheThreeMember2021-04-202021-04-200001760854nbx:OSA202104OrdinaryMember2021-01-012021-06-300001760854nbx:OSA202104OrdinaryMember2020-01-012020-06-300001760854nbx:OSA202104PerformanceMember2021-01-012021-06-300001760854nbx:OSA202104PerformanceMember2020-01-012020-06-300001760854nbx:OSA202106OrdinaryMembernbx:TrancheOneMember2021-06-212021-06-210001760854nbx:OSA202106OrdinaryMembernbx:TrancheTwoMember2021-06-212021-06-210001760854nbx:OSA202106OrdinaryMembernbx:TrancheThreeMember2021-06-212021-06-210001760854nbx:OSA202106OrdinaryMembernbx:TrancheOneMember2021-06-212021-06-210001760854nbx:OSA202106OrdinaryMembernbx:TrancheTwoMember2021-06-212021-06-210001760854nbx:OSA202106OrdinaryMembernbx:TrancheThreeMember2021-06-212021-06-210001760854nbx:OSA202106OrdinaryMember2021-01-012021-06-300001760854nbx:OSA202106OrdinaryMember2020-01-012020-06-300001760854nbx:OSA202106PerformanceMember2021-01-012021-06-300001760854nbx:OSA202106PerformanceMember2020-01-012020-06-300001760854nbx:OSAMember2021-01-012021-06-300001760854nbx:OSAMember2020-01-012020-06-300001760854nbx:AGA20181Member2021-01-012021-06-300001760854nbx:AGA20181Member2020-01-012020-06-300001760854nbx:AGA20182Member2021-01-012021-06-300001760854nbx:AGA20182Member2020-01-012020-06-300001760854nbx:AGA20191Membernbx:TrancheOneMember2019-03-292019-03-290001760854nbx:AGA20191Membernbx:TrancheTwoMember2019-03-292019-03-290001760854nbx:AGA20191Member2021-01-012021-06-300001760854nbx:AGA20191Member2020-01-012020-06-300001760854nbx:AGA2020Member2021-01-012021-06-300001760854nbx:AGA2020Member2020-01-012020-06-300001760854nbx:AGA2021Member2021-01-012021-06-300001760854nbx:AGA2021Member2020-01-012020-06-300001760854nbx:AGAMember2021-01-012021-06-300001760854nbx:AGAMember2020-01-012020-06-300001760854nbx:BSA2020Membernbx:TrancheOneMember2020-03-172020-03-170001760854nbx:BSA2020Membernbx:TrancheTwoMember2020-03-172020-03-170001760854nbx:AGA2020Membernbx:TrancheOneMember2020-03-112020-03-110001760854nbx:AGA2020Membernbx:TrancheTwoMember2020-03-112020-03-110001760854nbx:AGA2021Membernbx:TrancheOneMember2021-04-202021-04-200001760854nbx:TrancheTwoMembernbx:AGA2021Member2021-04-202021-04-200001760854nbx:HSBCBankAccountDenominatedInUSDollarsMember2021-01-012021-06-300001760854nbx:EuropeanInvestmentBankLoanAgreementMember2021-01-012021-06-300001760854ifrs-full:FloatingInterestRateMembernbx:EuropeanInvestmentBankLoanAgreementMember2021-01-012021-06-300001760854nbx:EuropeanInvestmentBankLoanAgreementMemberifrs-full:FixedInterestRateMember2021-01-012021-06-300001760854srt:MinimumMembernbx:EuropeanInvestmentBankLoanAgreementMember2021-06-3000017608542018-07-012018-07-31nbx:lease_contract0001760854nbx:MDAndersonCancerCenterNBTXR3Member2019-01-012021-06-300001760854ifrs-full:BottomOfRangeMembernbx:MDAndersonCancerCenterNBTXR3Member2021-01-012021-06-300001760854ifrs-full:TopOfRangeMembernbx:MDAndersonCancerCenterNBTXR3Member2021-01-012021-06-30


____________________________________________________________________________________________________________________________________________________________________________________________

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________

FORM 6-K
________________________

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: September 8, 2021

Commission File Number: 001-39777

________________________

NANOBIOTIX S.A.
(Exact name of registrant as specified in its charter)
_________________________

Nanobiotix S.A.
60 rue de Wattignies
75012 Paris, France
(Address of principal executive office)

_________________________


Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F:
☒ Form 20-F
☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐




______________________________________________________________________________________________
______________________________________________________________________________________________





This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (File Nos. 333-253062 and 333-257239).


EXHIBIT INDEX

ExhibitDescription
99.2
101The following materials from Nanobiotix S.A.’s Report on Form 6-K for the six months ended June 30, 2021 formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Unaudited interim condensed statements of consolidated financial position, (ii) Unaudited interim condensed statements of consolidated operations, (iii) Unaudited interim condensed statements of consolidated comprehensive loss, (iv) Unaudited interim condensed statements of consolidated changes in shareholders' equity, (v) Unaudited interim condensed statements of consolidated cash flows and (v) Notes to the unaudited Interim Condensed Consolidated Financial Statements.

† Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10). The omitted information is not material and would likely cause competitive harm to the registrant if publicly disclosed.




































SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NANOBIOTIX S.A.
/s/ LAURENT LEVY
By:Laurent Levy, Ph.D.
Title:Chairman of the Executive Board


Date: September 8, 2021



















































EXHIBIT 99.1


















NANOBIOTIX
HALF-YEAR FINANCIAL REPORT
From January 1, 2021 to June 30, 2021


September 8, 2021




























TABLE OF CONTENTS




Page
I.
1
1
1
7
8
9
9
II. 10
F-1
F-2
F-3
F-4
F-5
F-6
III.F-40

































INTERIM ACTIVITY REPORT

1. COMPANY INFORMATION

Nanobiotix, a société anonyme having its registered office at 60 rue de Wattignies, 75012 Paris, registered with the Paris registry of trade and companies under number 447 521 600 (“Nanobiotix” or the “Company” and, with its subsidiaries, the “Group”), is a French biotechnology company in advanced clinical development, pioneering physics-based approaches to expand treatment possibilities for patients with cancer. The Company's philosophy is rooted in one concept: pushing the boundaries of what is known to expand the possibilities of human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The Company also has subsidiaries in the United States (Cambridge, Massachusetts), France, Spain and Germany. Nanobiotix has been listed on the regulated market of Euronext in Paris since 2012 and on the Nasdaq Global Select Market in New York since December 2020.

Nanobiotix owns more than 30 patent families associated with three nanotechnology platforms for applications in (i) oncology, (ii) bioavailability and biodistribution and (iii) disorders of the central nervous system. The Company's resources are primarily devoted to the development of its main product candidate, NBTXR3, which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

2. SIGNIFICANT EVENTS DURING THE SIX MONTH PERIOD ENDED JUNE 30, 2021

Following the Company’s listing on the Nasdaq Global Select Market in December 2020, the Company remained focused during the first half of 2021 on advancing the registration of NBTXR3 in the United States and the European Union for the treatment of head and neck cancers, while also advancing its immunotherapy program (IO). The Company simultaneously continued to evaluate NBTXR3 in other indications such as lung, esophageal and pancreatic cancers.

2.1 POSITIVE RESULTS IN RECTAL CANCER (PEP503-RC-10001)

As previously announced, NBTXR3 clinical trials conducted by PharmaEngine, Inc. (“PharmaEngine”) in Asia, including the PEP503-RC-10001 open-label Phase I/II clinical trial with radiotherapy in combination with chemotherapy for patients with unresectable rectal cancer, are in the process of being concluded or terminated.

Primary and secondary endpoints of the PEP503-RC-10001 trial will assess the safety profile and determine the dose-limiting toxicity, evaluate the recommended dosage and assess the antitumor activity by evaluating the response rate of NBTXR3 administered by intratumoral injection and activated by external beam radiation, with concurrent chemotherapy treatment in patients with unresectable rectal cancer. The trial, which is being conducted at one site in Taiwan, was expected to treat up to 42 patients. PharmaEngine will implement the early termination and wind-down of this clinical trial in accordance with good clinical practice guidelines. The trial will be deemed completed when all enrolled patients have reached “end-of-study” and PharmaEngine issues a final study report in accordance with good clinical practice guidelines.

In January 2021, PharmaEngine presented first clinical results from this study at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI 2021). Intratumoral injection of NBTXR3 with concurrent chemo-radiation (CCRT) was feasible and the product candidate was well tolerated at all dose levels, and no adverse events (AEs) or serious adverse events (SAEs) associated with NBTXR3 were observed in the study. One dose-limiting toxicity associated with the injection procedure was observed (urinary tract infection). The most frequently reported AEs were diarrhea (approximately 45%), leukopenia (approximately 40%), and dermatitis (approximately 25%), however all were grade one or grade two. More than 70% of patients in the study showed objective tumor response after CCRT. Around 90% of patients underwent total mesorectal excision (surgery) and 17.6% achieved pathological complete response (pCR). 50% of patients receiving surgery in the study had good tumor regression (tumor regression grade 0 or 1 according to modified Ryan scheme). The recommended phase 2 dose (RP2D) was established at 22% of tumor volume.

2.2 FIRST PATIENT INJECTED WITH NBTXR3 IN A PATIENT WITH ESOPHAGEAL CANCER (MD ANDERSON, STUDY 2020-0122)

In January 2021, the first patient was injected in a phase I study evaluating NBTXR3 activated by radiation therapy with concurrent chemotherapy for adult patients (age > 18 years) with stage II-III adenocarcinoma of the esophagus that are treatment naïve and radiographically non-metastatic at screening. This trial is an open-label, single-arm, prospective phase I study consisting of two parts: (i) does-escalation to determine the RP2D of NBTXR3 activated by radiotherapy with concurrent chemotherapy, and (ii) expansion at RP2D with toxicity monitoring. The objectives of the study are the determination of dose-limiting toxicity, the maximum tolerated dose and RP2D.

1


This trial is being conducted at the University of Texas MD Anderson Cancer Center (“MD Anderson”) as part of an existing clinical collaborative arrangement between the Company and MD Anderson and does not represent incremental costs for the Company beyond previously announced financial terms.

This is the seventh indication in which NBTXR3 is undergoing clinical evaluation, either as a single agent activated by radiation therapy or in combination with other cancer therapies, including immunotherapies and chemotherapy.

2.3 NEW PRECLINICAL DATA PRESENTED AT THE FIRST AMERICAN ASSOCIATION OF CANCER RESEARCH (AACR) VIRTUAL SPECIAL CONFERENCE ON RADIATION SCIENCE AND MEDICINE

In March 2021, researchers from MD Anderson presented preclinical data in a poster presentation at the American Association of Cancer Research (AACR) Virtual Special Conference on Radiation Science and Medicine. This study examined NBTXR3 activated by radiotherapy in combination with anti-PD-1 along with TIGIT and LAG3 inhibitors in an in vivo anti-PD-1 resistant mouse model (344SQR). The data showed that the combination therapy of NBTXR3, activated by radiotherapy, in combination with anti-PD-1, anti-LAG3 and anti-TIGIT (Combo therapy) significantly promoted the proliferation activity of CD8+ T cells, improved local and distant tumor control and increased survival rate.

The anti-tumor efficacy of the Combo therapy was heavily dependent on CD4+ and CD8+ T cells. The data showed that the cured mice maintained significantly higher percentages of memory CD4+ and CD8+ T cells, as well as stronger anti-tumor immune activities than control, and those from the groups treated with the Combo therapy were immune to re-injections of tumor cells. Further, in this preclinical study, the Combo therapy augmented antitumor response in both irradiated and unirradiated (abscopal) tumors.

2.4 UPDATED RESULTS FROM PRIORITY HEAD AND NECK CANCER AND IMMUNOTHERAPY DEVELOPMENT PATHWAYS PRESENTED AT THE 2021 ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL ONCOLOGY

In June 2021, at the 2021 Annual Meeting of the American Society for Clinical Oncology (ASCO), Nanobiotix presented updated results from clinical studies of NBTXR3, in the treatment of head and neck cancers (squamous cell carcinomas of the head and neck; HNSCC) and in combination with immunotherapy for the treatment of advanced cancers.

Local control as a single agent for patients with head and neck cancer (Study 102 Expansion)

Study 102 Expansion, a phase I dose expansion study evaluating NBTXR3 as a single agent activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC, is evaluating a single dose of NBTXR3 at 22% of baseline tumor volume (the RP2D). Primary endpoints of the study are objective response rate (ORR) and complete response rate (CRR) of the primary tumor.

Updated data from Study 102 Expansion presented at ASCO further support NBTXR3 administration, followed by activation with radiotherapy, as feasible and well-tolerated. Six (6) serious adverse events (SAEs) related to NBTXR3 were observed across five (5) patients. A total of ten (10) deaths related to adverse events were reported. Four (4) deaths related to radiotherapy were observed, along with one (1) death from sepsis that was investigator assessed as related to radiotherapy and cancer, and possibly to NBTXR3.

At a median follow up of 8.1 months, evaluable patients (n=40) demonstrated a high primary tumor objective response rate, or ORR, of 82.5% and a 62.5% complete response rate, or CRR, (these percentages include one patient recorded by the principal investigator in the Clinical Observation Record (eCRF) as Unconfirmed Complete Response). These results are consistent with those observed in the dose escalation part of the study and suggest durability of efficacy.

Priming Immune Response and Immunotherapy Combination in Advanced Cancers (Study 1100)

Data presented by Nanobiotix during ASCO from its ongoing Study 1100, a phase I study of NBTXR3 activated by radiotherapy for patients with advanced cancers treated with an anti-PD-1 therapy showed that as of the data cut-off, NBTXR3 activated by radiotherapy and combined with anti-PD-1 induced local or distant tumor regression in 76.9% (10/13) of evaluable patients in the study, regardless of their prior exposure to anti-PD-1.

As of the data cut-off, the data showed that among anti-PD-1 naïve patients, 80% (4/5) had tumor regression and 60% (3/5) had investigator-assessed objective response, including one (1) complete response according to response evaluation criteria outlined in RECIST 1.1.

Results also show NBTXR3 plus radiotherapy could potentially stimulate immune response and convert anti-PD-1 non-responders into responders. In patients with prior primary or secondary resistance to anti-PD-1, 75% (6/8) had tumor regression and 50% (4/8) had investigator-assessed objective response. These included one (1) complete response and two (2) partial responses by RECIST 1.1, along with one (1) additional investigator-assessed
2


pathological complete response. Some patients in the study showed delayed tumor response and/or abscopal effect, suggesting NBTXR3 may potentially prime an immune response.

NBTXR3 administration by intratumoral injection was feasible and well-tolerated. As of the data cut-off date, the overall adverse event (AE) profile did not differ from what is expected with radiotherapy or anti-PD-1 agents. Sixteen serious AEs were observed, of which four (4) were identified as NBTXR3 or injection related.

2.5 PARTNERSHIPS

2.5.1 PharmaEngine

In March 2021, in light of disagreements over a number of issues with respect to the development of NBTXR3 in the Asia-Pacific region, Nanobiotix and PharmaEngine mutually agreed to terminate the licensing and collaboration agreement entered into in August 2012. Accordingly, on March 4, 2021, Nanobiotix and PharmaEngine entered into a termination and release agreement (the “Termination Agreement”). Under the Termination Agreement, Nanobiotix retained all rights to the development and commercialization of NBTXR3 in the Asia-Pacific region. Nanobiotix agreed to make total termination payments to PharmaEngine of up to $12.5 million in the aggregate.

PharmaEngine was eligible for and received a $2.5 million payment following the announcement of Nanobiotix’s collaboration with LianBio Oncology Limited ("LianBio"), a Hong Kong company, for the Asia-Pacific region. During the six months ended June 30, 2021, PharmaEngine also received $4.0 million in conjunction with the completion of various administrative steps in connection with the winding-up of the collaboration.

PharmaEngine will be eligible to receive an additional $1.0 million in administrative fees and a final payment of an additional $5 million upon a second regulatory approval of an NBTXR3-containing product in any jurisdiction of the world for any indication. PharmaEngine is entitled to receive a low-single digit tiered royalty based on net sales of NBTXR3 in the Asia-Pacific region for a 10-year period commencing on the corresponding first date of sales in the region.

As part of the Termination Agreement, PharmaEngine re-assigned to Nanobiotix rights for the development, manufacture, commercialization and exploitation of NBTXR3 in the Asia-Pacific region, as well as all development data, regulatory materials, and all regulatory approvals that are in the name of PharmaEngine or its affiliates. Consequently, NBTXR3 clinical trials conducted by PharmaEngine in Asia are in the process of being concluded or terminated (see in particular section 2.1 above).

Nanobiotix and PharmaEngine also agreed to a mutual release of all claims against the other party and its respective affiliates.

2.5.2 LianBio

On May 11, 2021, the Company entered into a strategic License, Development and Commercialization Agreement (the “LianBio Agreement”) with LianBio for the development and commercialization of NBTXR3, as a product activated by radiotherapy in the field of oncology, in key parts of Asia—the People’s Republic of China, Macau, Hong Kong, Thailand, Taiwan, South Korea and Singapore (collectively, the “Territory”). The Company has granted LianBio an exclusive royalty-bearing license which includes, subject to certain conditions, the right for LianBio to grant sublicenses to its affiliates and/or third-party subcontractors involved in the development of NBTXR3.

Obligations of the Parties

Under the LianBio Agreement, LianBio is exclusively responsible for the development and commercialization of NBTXR3 throughout the Territory, except for specified ongoing trials that the Company will conclude. The Company is responsible for the manufacturing of NBTXR3 and will be the exclusive supplier of NBTXR3 to LianBio.

Pursuant to the LianBio Agreement, LianBio will have to enroll a specified percentage of the worldwide total number of patients in the Company’s global phase III registrational study evaluating NBTXR3 for patients with locally advanced head and neck squamous cell carcinoma (NANORAY-312) and each of four other specified global registrational trials across indications and therapeutic combinations. For NANORAY-312, LianBio is expected to enroll approximately 100 patients based on the Group’s current worldwide enrollment expectations. In the event that LianBio does not meet its enrollment undertaking for these trials, LianBio will be responsible for covering certain incremental costs incurred by the Company as a result. Otherwise, LianBio will fund all development and commercialization expenses in the Territory, and the Company will fund all development and commercialization expenses in all other geographies.

For all non-registrational trials (i.e., Phase I or Phase II trials) undertaken to support the development and approval of NBTXR3, the Company and LianBio have agreed to provide each other with rights to access all clinical efficacy and safety data. For additional registrational trials, the Company and LianBio have agreed to provide each other with
3


rights to access all clinical safety data and to provide an opportunity to license and right of reference to efficacy data, subject to certain cost- sharing and/or enrollment undertakings.

Pursuant to the LianBio Agreement, LianBio has sole control over commercialization in the Territory and is responsible for all costs and expenses of such commercialization. LianBio, or its affiliates and/or sublicensees, is solely responsible for all communications, filings with, as well as approvals sought from regulatory authorities to obtain all marketing authorizations in relation to NBTXR3 in the Territory.

As consideration for entering into the LianBio Agreement, the Company received a non-refundable upfront payment from LianBio of $20.0 million in June 2021.

The Company is also eligible to receive up to an aggregate of $220 million in potential contingent, development and commercialization milestone payments. The Company will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the Territory, subject to downward adjustment based on enrollment incentives and customary country-by-country competition- and intellectual property-related triggers. Royalties will be payable on a product-by-product and country-by-country basis until the latest of (i) the expiration of the last-to-expire valid claim of a licensed patent covering NBTXR3, (ii) the expiration of regulatory exclusivity of NBTXR3, or (iii) the ten-year anniversary of the first commercial sale of NBTXR3. Upon the expiration of the royalty term in a given country, LianBio shall be granted a perpetual, royalty-free, sublicensable license in such country.

Responsibility

Pursuant to the LianBio Agreement, the collaboration is implemented under the supervision of a joint steering committee, which will include an equal number of representatives of each party, including one member of senior leadership of each of LianBio and the Company, and will meet on a regular basis to provide oversight and facilitate information sharing between LianBio and the Company. In the event of a dispute among representatives at the joint steering committee, the matters shall be escalated to appropriate senior officers of LianBio and the Company. In the event such senior officers cannot reach an agreement on the matters at hand within a set timeframe, LianBio and the Company have agreed that one of the parties shall have the final decision-making authority on certain specific matters, without prejudice to any contractual obligations set out under the LianBio Agreement.

Pursuant to the LianBio Agreement, LianBio’s Territory-specific development and regulatory plan and commercialization in the Territory will be conducted pursuant to LianBio’s Territory-specific plans, which will be subject to periodic updates and joint steering committee review.

The Company retains the first right to prosecute, maintain and defend, at its expense, all of its licensed patents in the Territory. In the event that it elects not to prosecute or maintain any such patent in the Territory or not to defend a patent in the Territory, the Company has agreed to notify LianBio, and LianBio shall have the right, but not the obligation, to assume such prosecution, maintenance or defense at its own expense. LianBio shall have the first right to enforce, at its expense, the Company’s intellectual property against infringement in the Territory, except where the Company is enforcing such intellectual property both within and outside the Territory against such infringement. In the event that LianBio elects not to enforce the Company’s intellectual property against infringement in the Territory, it has agreed to notify the Company, and the Company will have the right to enforce such intellectual property at its expense.

The Company and LianBio have agreed to customary confidentiality obligations with respect to trade secrets and confidential or proprietary information disclosed in connection with their respective performance under the LianBio Agreement, subject to customary exceptions. The Company and LianBio have agreed to provide customary indemnification to one another for claims relating to their respective obligations under the LianBio Agreement. LianBio has agreed to maintain a customary liability insurance policy during the term of the LianBio Agreement.

LianBio has undertaken to conduct and ensure that all of its affiliates, sublicensees and subcontractors conduct their business under the LianBio Agreement in accordance with applicable laws and, to the extent applicable with respect to certain development activities, FDA and EU medical device requirements.

Dispute Resolution

The LianBio Agreement provides a dispute resolution mechanism with respect to interpretation of rights or obligations and any alleged breaches under the LianBio Agreement. The dispute resolution mechanism provides for the escalation of such matters to the joint steering committee and, if unresolved following such escalation, further escalation to the respective chief executive officers of us and LianBio to negotiate in good faith. If such matter is unable to be resolved, the LianBio Agreement provides for arbitration, except that certain disputes relating to intellectual property matters are not subject to such an arbitration requirement and may be brought in courts of competent jurisdiction.

4


Intellectual Property

The Company and LianBio retain ownership of their respective pre-existing intellectual property, other inventions and discoveries relating to NBTXR3 made in the course of performing obligations under the LianBio Agreement made solely by the Company or LianBio, as the case may be, will be owned by the respective inventor. To the extent an invention or discovery relating to NBTXR3 is made by LianBio and the Company together, such invention and any related patents will be jointly owned by LianBio and the Company. The rights to file, prosecute and enforce such jointly-owned patents will be determined by mutual agreement through the joint steering committee.

Termination

Unless terminated earlier, the LianBio Agreement will remain in effect for so long as royalties are payable under the LianBio Agreement. The LianBio Agreement may be terminated earlier by either party if the other party commits an uncured material breach. In any event where LianBio has a termination right based on a material breach by the Company, LianBio may elect in lieu of termination to continue the LianBio Agreement, subject to a downward percentage reduction in all milestone and royalty payments.

Either party may also terminate the agreement in the connection with the occurrence of certain insolvency or bankruptcy events with respect to the other party. LianBio may terminate the agreement following a change in control of the Company, subject to a specified notice period. The Company may terminate the agreement under certain circumstances in connection with a change of control of LianBio. The Company may also terminate the LianBio Agreement in the event that LianBio or its affiliates bring or join any challenge to the validity or enforceability of the Company’s patents, subject to certain limited exceptions.

Termination of the LianBio Agreement will terminate all rights, licenses and sublicenses under the agreement, subject to the agreement of the Company, in certain cases, to negotiate in good faith with sublicensees regarding a potential direct license.

2.5.3 Curadigm collaboration with Sanofi

In January 2021, a research project involving the nanoprimer technology held by Curadigm, a wholly-owned subsidiary, was selected for the Sanofi iTech Awards Program for its potential to significantly improve gene therapy development. Curadigm has entered into a one-year collaboration agreement with Sanofi that is expected to include direct funding and scientific exchanges. The goal of the project is to establish proof-of-concept for the nanoprimer as a combination product that could improve treatment outcomes for gene therapy product candidates.

2.6 EVOLUTION OF THE SUPERVISORY BOARD AND THE EXECUTIVE BOARD

Evolution of the Supervisory Board

On May 25, 2021, Mr. Laurent Condomine, member and chairman of the supervisory board of the Company (the “Supervisory Board”) for 11 years, resigned with immediate effect. To fill this vacancy, on the same date, the Supervisory Board appointed Dr. Gary Phillips as a member of the Supervisory Board for the remainder of Mr. Laurent Condomine’s term of office, subject to the ratification of the appointment by the next ordinary shareholders’ meeting, and elected him as chairman of the Supervisory Board. Dr. Gary Phillips was also appointed on such date as a member of the Company’s audit committee and appointments and compensation committee.

During the same meeting, the Supervisory Board acknowledged that Dr. Gary Phillips is independent in accordance with Nasdaq's listing rules and Rule 10A-3 of the United States Exchange Act as well as the criteria established by the Code of corporate governance as published by MiddleNext in September 2016.

Dr Phillips brings decades of experience in the pharmaceutical and healthcare industries where he has led commercial operations, clinical medicine, business strategy, and development functions. Dr. Phillips will provide extensive guidance as the Company continues to advance its global development strategy with its planned second clinical registration pathway in head and neck cancer and its immunotherapy pathway as key focus areas.

Dr. Phillips, who is currently president and chief executive officer of OrphoMed, Inc. (OrphoMed), in the United States, brings decades of experience in the pharmaceutical and healthcare industries where he has led commercial operations, clinical medicine, business strategy, and development functions. Before joining OrphoMed in 2018, Dr. Phillips worked with Mallinckrodt Pharmaceuticals, where he had served as Executive Vice President and Chief Strategy Officer since 2013. Prior to that role, he was Head of Global Health & Healthcare Industries at the World Economic Forum, served as President of Reckitt Benckiser Pharmaceuticals North America (now Indivior), and held dual roles as President, U.S. Surgical and Pharmaceuticals and Global Head of Pharmaceuticals at Bausch & Lomb. In addition, Dr. Phillips has served in executive roles at Merck Serono, Novartis, and Wyeth. Dr. Phillips earned a B.A. in Biochemistry with Summa Cum Laude and Phi Beta Kappa distinctions from the College of Arts and Sciences
5


at the University of Pennsylvania, an MBA from the Wharton School at the University of Pennsylvania, and an M.D. with Alpha Omega Alpha distinction from the School of Medicine at the University of Pennsylvania. Dr. Phillips maintains an active medical license and practiced as a general medicine clinician/officer in the U.S. Navy, from which he was honorably discharged as a lieutenant commander.

Evolution of the Executive Board

On May 31, 2021, the Supervisory Board appointed Bart Van Rhijn as a member of the executive board of the Company (the “Executive Board”). It is specified that on May 11, 2021, Bart Van Rhijn entered into an employment agreement with Nanobiotix Corp. pursuant to which Bart Van Rhijn shall perform duties of Chief Financial Officer as from June 1, 2021.

Mr. Van Rhijn brings proven capabilities in global financial management, business development and pharmaceutical commercialization as the Company prepares for the planned launch of its second clinical registration study for potential first-in-class radioenhancer NBTXR3 in head and neck cancer (NANORAY-312), continued development in immunotherapy, and planned expansion across solid tumor types and therapeutic combinations.

Mr. Van Rhijn brings extensive experience in consultancy, technology, and life sciences industries and joins Nanobiotix after nearly 3 years as Chief Financial Officer at Servier Pharmaceuticals, LLC (Servier US). Prior to Servier US, he held leadership roles in prominent organizations in Europe and North America, including PricewaterhouseCoopers, Philips and Galderma in Head of Tax, Senior Director of Mergers and Acquisitions, and Head of Finance positions. Mr. Van Rhijn’s track record reflects a relentless commitment to streamlining business operations, driving growth, and unlocking value. His varied experiences include the successful reorganization of a healthcare technology-enabled services business, coordination of strategic financing transactions, and the efficient scaling of commercial businesses. Mr. Van Rhijn has a strong commitment to organizational health and empowers his teams to embrace innovation, challenge the status quo, and drive optimal results while putting patients and customers first.

Mr. Van Rhijn received master’s degrees in Civil Law and Tax Law at Leiden University, The Netherlands, obtained his MBA with honors from Babson’s Olin School of Management, and his Certified Management Accountant (CMA) certification from the Institute of Management Accounts. In addition, Mr. Van Rhijn serves on the Advisory Board of a Boston-based healthcare start-up and is a venture partner at an emerging technology fund.

Mr. Van Rhijn succeeded Philippe Mauberna, who stepped down from his roles as Chief Financial Officer and Executive Board member after 8 years of service to the Company.

The Company and Philippe Mauberna mutually agreed to terminate his employment agreement as Chief Financial Officer, effective June 30, 2021 and, in this context, entered into a termination agreement on May 19, 2021, the terms of which were approved by the Supervisory Board on April 6, 2021. Pursuant to this agreement, Philippe Mauberna was in particular entitled to an indemnity of €255,000. He also kept the benefit of his 2021 variable compensation (on a prorata basis), subject however to the achievement of the performance objectives set by the Executive Board. In addition, the Executive Board decided to lift, as from June 30, 2021, the continued service condition to which the exercise or definitive acquisition of all incentive instruments held by Philippe Mauberna are subject, notwithstanding the termination of his positions within the Group, and to accelerate the vesting of the OSA 2020 he holds, enabling Philippe Mauberna to exercise all of them. In order to avoid a negative impact on the Company's share price, Philippe Mauberna agreed that the sale of his shares would be restricted. Finally, as from June 30, 2021, Philippe Mauberna was released from his non-compete undertaking.

Furthermore, on May 31, 2021, Philippe Mauberna resigned from his office of Executive Board member, effective immediately as well as from all other positions he holds within the Group.

2.7 COVID-19 PANDEMIC

The global COVID-19 pandemic has impacted Nanobiotix's development plan, causing certain delays in the implementation and execution of clinical trials. Despite this, the overall development plan continues, prioritizing head and neck cancer and immuno-oncology.

Four clinical studies have been active during the period beginning March 2020. Study, site and subject risks were assessed as follows:

The Act.In.Sarc study had study close-out in first quarter of 2021 with data analysis and reporting of the clinical study. Patient enrollment had been completed. The study ended later than planned, as patient visits were delayed to ensure that all patients could return to the clinical site for their last follow-up visit. Only 5 patients were unable to return to sites for follow-up visits due to the COVID-19 pandemic. The clinical study sites were closed and Clinical Investigation Report finalized.

6


The 102 Expansion study has been ongoing during the COVID-19 pandemic, with sites active in France, Spain and Hungary. Patient enrollment was delayed due to: patient hesitancy to go to hospital sites; certain instances of positive COVID-19 testing, which excluded affected patients from enrollment; site staffing issues, with decreasing time on site and remote work, negatively affecting the Company’s ability to engage in patient recruitment activities. This also adversely impacted timely data review and updates. Monitoring visits were curtailed to one on-site visit per month at many sites, but remote monitoring was allowed. Patient follow-up visits were not affected.

Study 1100 has been ongoing in the United States during the COVID-19 pandemic. Patient recruitment was adversely delayed due to patient hesitancy to participate during the pandemic, site staff diverted to other hospital duties and de-prioritization of clinical studies at sites. Some delays were experienced with data review and update and monitoring visits were remote. Patient follow-up was not affected.

NANORAY-312, a global study, is in the study initiation phase with activities focused on site selection and study approvals from regulatory and Ethics Committee/Institutional Review Boards. The COVID-19 pandemic has disrupted routine hospital services globally, including the halting or delay of procedures, such as this study, that are deemed elective in the US and other countries and affecting study initiation efforts. These activities were further affected by sites decreased staffing and increased review time for study approvals (decreased frequency of meetings). Additionally, pre-site selection visits were conducted remotely, rather than on-site, in many regions. The Company will closely monitor site activation and patient recruitment in light of evolving conditions within the hospital setting and patient hesitancy to participate in hospital-based clinical studies during the ongoing pandemic.

Regarding MD Anderson studies, five of the six studies expected to be initiated by year-end 2021 are open and enrolling of which three have been enrolling as expected and two have seen slower recruitment and enrollment. MD Anderson generated specific policies and standard operating procedures to protect patients and staff alike. We have not observed delays in the administration of NBTXR3 for patients enrolled in ongoing studies. However, the COVID-19 pandemic has affected patient recruitment and has created delays in patient follow up, especially for those patients that are not local to the Houston metropolitan area.

Despite some of the delay experienced in the studies, the COVID-19 pandemic did not negatively impact liquidity and/or funding sources.

3. COMPANY ACTIVITY OVER THE FIRST HALF OF 2021

A. Revenue and other income

The revenue of Nanobiotix for the six month period ended on June 30, 2021 mainly correspond to the rebilling of materials and services linked to the activities planned under the Company’s partnership agreement with PharmaEngine before its termination.

The other income for the six month period ended on June 30, 2021, is mainly composed of research tax credit which increased by €0.3 million due to the increase of the R&D expenses.
For the six month period ended June 30,
(in thousands of euros)20212020
Services5 37 
Other sales5  
Total revenues10 37 
Research tax credit1,227 888 
Subsidies62 494 
Other20 28 
Total other income1,309 1,411 
Total revenues and other income1,319 1,448 











7


B. Costs

The operating costs of the first half of 2021 totalled €31.1 million compared to €19.8 million in the first half of 2020. The relative weight of R&D expenses compared to SG&A, decreased from one half to the next with 50% and 33% of expenses incurred respectively in the first half of 2021 (first semester of 2020: 66% and 34%) primarily resulting from the change in other operating income and expenses from 0% in the first half of 2020 to 17% in the first half of 2021.

The Company has made payments for a cumulative amount of $6.5 million (€5.4 million converted at the exchange rate on the payment date) to PharmaEngine in accordance with the Termination Agreement signed between the parties which has been accounted for in other operating income and expenses. See Note 16 Operating expenses for more information.

For the six month period endedFor the six month period ended
(in thousands of euros)June 30, 2021Relative weightJune 30, 2020Relative weight
R&D expenses
15,506 50 %13,077 66 %
SG&A expenses
10,176 33 %6,755 34 %
Other operating income and expenses
5,414 17 %— — %
Total operating expenses31,096 100 %19,832 100 %

C. Results

The operating result is a loss of €29.8 million for the six months ended June 30, 2021 compared to a loss of €18.4
million for the same period in 2020.

The financial result is a loss of €0.6 million for the six months ended June 30, 2021 compared to a loss of €2.2 million for the same period in 2020.

The net loss for the six month period ended June 30, 2021 was €30.4 million compared to a net loss of €20.6 million
for the same period in 2020.

4. FUTURE PROSPECTS

NBTXR3 is currently being evaluated as a potential monotherapy and combination product in seven clinical trials in patients with various forms of cancer.

As a single agent, the Company is currently focused on the head and neck cancer indication (locally advanced carcinoma of the oral cavity or oropharynx). A phase I dose expansion study - study 102 Expansion - is currently ongoing. We expect to report an analysis of progression free survival (PFS) and overall survival (OS) from 41 evaluable patients in Study 102 at a medical conference during the fourth quarter of 2021. The Company is preparing to launch a phase III registrational study - NANORAY-312 - that it expects to initiate late in the fourth quarter of 2021.

In addition, the Company is focused on its phase I trial - study 1100 - conducted in the United States assessing NBTXR3 activated by radiotherapy in combination with an anti-PD-1 in patients with locoregional recurrence (LRR) or metastatic recurrence (M/R) of head and neck cancer, lung and/or liver metastases. This program aims to assess the potential of NBTXR3 activated by radiotherapy in combination with immune checkpoint inhibitors (ICIs) to (i) convert non-responders to ICIs in responders, (ii) provide better local and systemic disease control and (iii) increase survival. We expect to provide updated data including approximately 16 evaluable patients at a medical conference during the fourth quarter of 2021 and plan to initiate discussions with FDA regarding potential registration pathway for NBTXR3 immunotherapy combination in H2 2021. The Company is on-track to report recommended Phase II dose for each cohort in 2022.

Concurrently, the Company has initiated three phase I and two phase II studies in collaboration with MD Anderson evaluating NBTXR3 as a single agent in pancreatic and lung cancer, in combination with immunotherapy in head and neck cancer and solid tumors, and in combination with chemotherapy in esophageal cancer.

In soft tissue sarcoma, the primary endpoint of the phase II/III study (Act.In.Sarc) was met and published in 2018 and the follow-up of patients in this study is ongoing. Given the marketing authorization of NBTXR3 in Europe under the brand name Hensify® for the treatment of locally advanced soft tissue sarcoma of the extremities and trunk wall, the Company is currently preparing a post-registrational study - study 401 - in the European Union which will continue to evaluate the safety and efficacy of NBTXR3 and will provide patients with soft tissue sarcoma with access to the product.

LianBio will collaborate in the development of NBTXR3 in Asia Pacific, and contribute to patient enrollment in five future global registrational studies across several tumor types and therapeutic combinations. LianBio will also
8


support the expansion of global phase III registrational study in head and neck cancer into Greater China, with longer term strategic alignment across multiple tumor indications and therapeutic combinations.

5. MAIN RISKS AND UNCERTAINTIES

The main risks and uncertainties that the Company may face in the remaining six months of the financial year are identical to those presented in the section 1.5 of the Company’s universal registration document filed with the French Financial market authority (l’Autorité des marchés financiers or the “AMF”) on April 7, 2021 under number D.21-0272 (copies of which are available on the Company’s website (www.nanobiotix.com)) (the “2020 URD”) and the Company’s Annual Report on Form 20-F, as amended, for the year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission on April 7, 2021 (the “2020 20-F”), with the exception of the risk detailed below:

If we fail to develop or maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results.

As a new public reporting company in the United States, we will be required pursuant to Section 404(a) of the Sarbanes-Oxley Act of 2002 to furnish a report by our management that assesses our internal control over financial reporting as of year-end in our Annual Reports on Form 20-F, commencing with an initial report as of December 31, 2021 to be included in our Annual Report for the fiscal year ending December 31, 2021.

Prior to the issuance of our interim financial statements as of and for the six-months ended June 30, 2021, a deficiency, which constituted a material weakness in our internal control over financial reporting, was identified. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

A material adjustment was made to our interim financial statements as of and for the six-months ended June 30, 2021 prior to their issuance which resulted from a deficiency in the controls over the evaluation of certain contracts and the related accounting. The identified deficiency related to the timing of the recognition of expenses associated with new contracts signed with certain contract research organizations for one of our clinical trials. Specifically, we made advance payments that were recorded as expenses of the period instead of prepaid expenses (the misstatement inappropriately increased the R&D expenses). Consequently, a material weakness is being disclosed in connection with the reporting of our interim financial statements.

Our management believes that the interim financial statements included in this report, which reflect this adjustment, present fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with IFRS. The material weakness did not result in material adjustments, or restatements, of our audited consolidated financial statements or disclosures for any prior period previously reported by us.

Under the supervision of management and the oversight of our Audit Committee, the Company is in the process of taking remedial actions to address the material weakness that has been identified. However, if our remedial measures are insufficient to address the material weakness or if additional deficiencies in our internal control over financial reporting are discovered or occur in the future, we may not be able to timely or accurately report our financial position, results of operations or cash flows or maintain effective disclosure controls and procedures.

6. KEY TRANSACTIONS WITH RELATED PARTIES

No significant transactions with related parties have occurred in the first half of 2021 other than the compensation of directors and the termination agreement entered into on May 19, 2021 with Mr. Mauberna (see section 2.6 above for more details).

















9


UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

TABLE OF CONTENTS


F-1
F-2
F-3
F-4
F-5
F-6
1.F-6
2.F-7
3.F-9
4.F-10
5.F-11
6.F-12
7.F-12
8.F-13
9.F-14
10.F-14
11.F-16
12.F-17
13.F-20
14.F-21
15.F-22
16.F-24
17.F-27
18.F-37
19.F-38
20.F-38
21.F-38
22.F-39
23.F-39












10


INTERIM CONDENSED STATEMENTS OF CONSOLIDATED FINANCIAL POSITION
(Amounts in thousands of euros)

As of
NotesJune 30, 2021December 31, 2020
ASSETS
Non-current assets
Intangible assets512 21 
Property, plant and equipment67,535 8,256 
Non-current financial assets7498 505 
Total non-current assets8,045 8,782 
Current assets
Trade receivables8.1 62 
Other current assets8.213,534 6,035 
Cash and cash equivalents9102,336 119,151 
Total current assets115,870 125,248 
TOTAL ASSETS123,915 134,030 

As of
NotesJune 30, 2021December 31, 2020
LIABILITIES AND SHAREHOLDER’S EQUITY
Shareholders’ equity
Share capital10.11,045 1,033 
Premiums related to share capital10.1255,782 255,735 
Accumulated other comprehensive income513 555 
Treasury shares(212)(196)
Reserve(185,276)(153,069)
Net loss for the period(30,420)(33,590)
Total shareholders’ equity41,431 70,468 
Non-current liabilities
Non-current provisions11.2457 414 
Non-current financial liabilities1243,988 44,107 
Total non-current liabilities44,445 44,522 
Current liabilities
Current provisions11.1430 40 
Current financial liabilities126,730 4,872 
Trade payables and other payables13.18,813 7,106 
Other current liabilities13.25,510 7,022 
Deferred revenues and contract liabilities13.316,555  
Total current liabilities38,038 19,041 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY123,915 134,030 

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.







F-1


INTERIM CONDENSED STATEMENTS OF CONSOLIDATED OPERATIONS
(Amounts in thousands of euros, except per share numbers)

For the six month period ended
NotesJune 30, 2021June 30, 2020
Revenues and other income
Revenues1510 37 
Other income151,309 1,411 
Total revenues and other income1,319 1,448 
Research and development expenses16.1(15,506)(13,077)
Selling, general and administrative expenses16.2(10,176)(6,755)
Other operating income and expenses
16.5(5,414) 
Total operating expenses(31,096)(19,832)
Operating income (loss)(29,778)(18,384)
Financial income182,511 234 
Financial expenses18(3,152)(2,428)
Financial income (loss)(640)(2,194)
Income tax(2)(1)
Net loss for the period(30,420)(20,579)
Basic loss per share (euros/share)20(0.88)(0.91)
Diluted loss per share (euros/share)20(0.88)(0.91)

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.




































F-2


INTERIM CONDENSED STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS
(Amounts in thousands of euros)

For the six month period ended
NotesJune 30, 2021June 30, 2020
Net loss for the period(30,420)(20,579)
Tax impact  
Other comprehensive loss that will not be reclassified subsequently to income or loss  
Currency translation adjustment(42)(5)
Tax impact  
Other comprehensive income that may be reclassified subsequently to income or loss(42)(5)
Total comprehensive loss(30,462)(20,584)

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.













































F-3


INTERIM CONDENSED STATEMENT OF CONSOLIDATED CHANGES IN SHAREHOLDERS’ EQUITY
(Amounts in thousands of euros, except number of shares)

Share capital
Ordinary shares
NotesNumber of
 shares
Amount
Premiums
related to
share capital
Accumulated
other
comprehensive
income (loss)
Treasury
shares
Reserve
Net loss
for the
period
Total
shareholders’
equity
As of December 31, 202034,432,122 1,033 255,735 555 (196)(153,069)(33,590)70,468 
Net loss for the period— — — — — — (30,420)(30,420)
Currency translation adjustments— — — (42)— — — (42)
Total comprehensive loss   (42)  (30,420)(30,462)
Allocation of prior period loss— — — — — (33,590)33,590  
Capital increase, net393,750 12 (12)— — — —  
Subscription of warrants10.3— — 43 — — — — 43 
Share-based payment17— — — — — 1,398 — 1,398 
Treasury shares— — — — (16)— — (16)
Other movements— — 16 — — (16)—  
As of June 30, 202134,825,872 1,045 255,782 513 (212)(185,276)(30,420)41,431 

Share capital
Ordinary shares
NotesNumber of
 shares
Amount
Premiums
related to
share capital
Accumulated
other
comprehensive
income (loss)
Treasury
shares
Reserve
Net loss
for the
period
Total
shareholders’
equity
As of December 31, 201922,415,039 672 153,139 433 (169)(105,070)(50,915)(1,909)
Net loss for the period— — — — — — (20,579)(20,579)
Currency translation adjustments— — — (5)— — — (5)
Total comprehensive loss   (5)  (20,579)(20,584)
Allocation of prior period loss— — — — — (50,915)50,915  
Capital increase, net316,083 9 — — — (9)—  
Subscription of warrants10.3— — 5 — — — — 5 
Share-based payment17— — — — — 1,542 — 1,542 
Treasury shares— — — — (74)— — (74)
U.S. Initial public offering costs offset— — (1,175)— — — — (1,175)
As of June 30, 202022,731,122 682 151,968 428 (243)(154,451)(20,579)(22,194)

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.
F-4


INTERIM CONDENSED STATEMENTS OF CONSOLIDATED CASH FLOWS
(Amounts in thousands of euros)

For the six month period ended
NotesJune 30, 2021June 30, 2020
Cash flows used in operating activities  
Net loss for the period(30,420)(20,579)
Elimination of other non-cash, non-operating income and expenses
Depreciation and amortization16.4801 906 
Provisions11432 (126)
Expenses related to share-based payments171,398 1,542 
Cost of net debt1,066 1,046 
Impact of deferred income related to financial liabilities discounting effect2,046 1,343 
Other charges with no impact on cash4 3 
Cash flows used in operations, before tax and changes in working capital(24,673)(15,864)
(Increase) / Decrease in trade receivables8.162 (39)
(Increase) / Decrease in Research tax credit receivable
8.2 3,314 
(Increase) / Decrease in other receivables8.2(7,504)(918)
Increase (Decrease) in trade and other payables13.12,053 192 
Increase / (Decrease) in other current liabilities13.2(1,442)435 
Increase in deferred income and contract liabilities13.316,434  
Changes in operating working capital9,602 2,985 
Net cash flows used in operating activities(15,071)(12,879)
Cash flows from (used in) investing activities
Acquisitions of intangible assets5(4)(17)
Acquisitions of property, plant and equipment6(45)(57)
Addition in non-current financial assets7 (9)
Net cash flows from (used in) investing activities(50)(83)
Cash flows from financing activities
Warrants subscription10.143 5 
Transaction costs(349)(261)
Increase in loans and conditional advances12 5,350 
Loans repayments12(250) 
Payment of lease liabilities
12(644)(171)
Interest paid 12(350)(350)
Charges of lease debt interest12(152)(169)
Net cash flows from financing activities(1,703)4,404 
Effect of exchange rates changes on cash8 54 
Net increase (decrease) in cash and cash equivalents(16,814)(8,505)
Net cash and cash equivalents at beginning of period119,151 35,094 
Net cash and cash equivalents at end of period9102,336 26,590 

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.
F-5


NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS
AS OF JUNE 30, 2021

1. Company information

Overview of the Company

Nanobiotix S.A. (“Nanobiotix” or the “Company” and, with its subsidiaries, the “Group”) is a French biotechnology company in advanced clinical development, pioneering physics-based approaches to expand treatment possibilities for patients with cancer. The Company's philosophy is rooted in one concept: pushing the boundaries of what is known to expand the possibilities of human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris (France). The Company also has subsidiaries in the United States (Cambridge, Massachusetts), France, Spain and Germany. Nanobiotix has been listed on the regulated market of Euronext in Paris since 2012 and on the Nasdaq Global Select Market in New York since December 2020.

Nanobiotix owns more than 30 patent families associated with three nanotechnology platforms for applications in (i) oncology, (ii) bioavailability and (iii) biodistribution and disorders of the central nervous system. The Company's resources are primarily devoted to the development of its main product candidate, NBTXR3, which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

Key events of the six month period ended June 30, 2021

Nanobiotix and PharmaEngine mutually agree to terminate their collaboration

In March 2021, in light of disagreements over a number of issues with respect to the development of NBTXR3 in the Asia-Pacific region, Nanobiotix and PharmaEngine mutually agreed to terminate the licensing and collaboration agreement entered into in August 2012. Accordingly, on March 4, 2021, Nanobiotix and PharmaEngine entered into a termination and release agreement (the “Termination Agreement”). Under the Termination Agreement, Nanobiotix retained all rights to the development and commercialization of NBTXR3 in the Asia-Pacific region. Nanobiotix agreed to make total termination payments to PharmaEngine of up to $12.5 million in the aggregate as described below.

PharmaEngine was eligible for and received a $2.5 million payment following the announcement of Nanobiotix’s collaboration with LianBio for the Asia-Pacific region. During the six months ended June 30, 2021, PharmaEngine also received $4.0 million in conjunction with the completion of various administrative steps in connection with the winding-up of the collaboration.

PharmaEngine will be eligible to receive an additional $1.0 million in administrative fees and a final payment of an additional $5.0 million upon a second regulatory approval of an NBTXR3-containing product in any jurisdiction of the world for any indication. PharmaEngine is entitled to receive a low-single digit tiered royalty based on net sales of NBTXR3 in the Asia-Pacific region for a 10-year period commencing on the corresponding first date of sales in the region. As of June 30, 2021, these future payments were not accrued because the triggering events have not occurred.

As part of the Termination Agreement, PharmaEngine re-assigned to Nanobiotix rights for the development, manufacture, commercialization and exploitation of NBTXR3 in the Asia-Pacific region, as well as all development data, regulatory materials, and all regulatory approvals that are in the name of PharmaEngine or its affiliates. Consequently, NBTXR3 clinical trials conducted by PharmaEngine in Asia are in the process of being concluded or terminated.

Nanobiotix and PharmaEngine also agreed to a mutual release of all claims against the other party and its respective affiliates.

Nanobiotix partners with LianBio for the development and commercialization of NBTXR3 in several oncology indications and in combination with several anti-cancer therapies, in China and other Asian markets

In May 2021, Nanobiotix entered into a partnership with LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize Nanobiotix’s lead product candidate, NBTXR3 into Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand.

LianBio will collaborate in the development of NBTXR3 in Asia Pacific, and contribute to patient enrollment in five future global registrational studies across several tumor types and therapeutic combinations including immunotherapy. LianBio will also support the expansion of global phase III registrational study in head and neck
F-6


cancer into Greater China with longer term strategic alignment across multiple tumor indications and therapeutic combinations.

Under the terms of the agreement, the Company received a $20 million upfront payment and is entitled to receive up to an aggregate of $220 million in potential contingent, development and commercialization milestone payments. The Company will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. LianBio will fund all development and commercialization expenses in the collaboration territory, and the Company will continue to fund all development and commercialization expenses in all other geographies.

Nanobiotix announces the appointment of Dr. Gary Phillips as Chairman of the Supervisory Board

In May 2021, Dr. Gary Phillips was appointed Chairman of the Company's supervisory board of the Company (“the “Supervisory Board”). Dr Phillips succeeded Laurent Condomine, who retired from the Supervisory Board after 11 years of leadership.

Nanobiotix announces the appointment of Bart Van Rhijn as Chief Financial Officer and member of the executive board of the Company to support its international expansion

On June 1, 2021, the Company announced the appointment of Bart Van Rhijn, MBA, as Chief Financial Officer and member of the executive board of the Company (the “Executive Board”). Mr. Van Rhijn brings proven capabilities in global financial management, business development and pharmaceutical commercialization as the Company prepares for the planned launch of its second clinical registration study for NBTXR3 in head and neck cancer (NANORAY-312), continued development in immunotherapy, and planned expansion across solid tumor types and therapeutic combinations. He succeeded Philippe Mauberna, who stepped down from his roles as Chief Financial Officer and Executive Board member after 8 years of service to the Company.

2. General information, statement of compliance and basis of presentation

General principles

The interim condensed consolidated financial statements as of June 30, 2021 and for the six month period ended June 30, 2021 were prepared under the supervision of the management of the Company and were approved by the Executive Board and reviewed by the Supervisory Board on September 8, 2021.

All amounts in the interim condensed consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items.

The preparation of the interim condensed consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. See Note 3.2 Use of judgement, estimates and assumptions.

The summarized interim consolidated financial statements of the Company have been prepared in compliance with IAS 34 – “Interim Financial Reporting”. As they are interim condensed financial statements, they do not contain all information required for the consolidated annual financial statements and should therefore be read in conjunction with the consolidated financial statements of the Company for the financial year ended December 31, 2020 as described below.

The interim condensed consolidated financial statements were prepared on a going concern basis. The Executive Board determined it is appropriate to apply a going concern assumption because the Company’s historical losses are due to the innovative nature of the products it is developing, which necessitates a research and development phase spanning multiple years. With cash and cash equivalents of €102.3 million as of June 30, 2021, the Company believes it has sufficient resources to continue operating for at least twelve months following the interim condensed consolidated financial statements’ publication.

Seasonality of the Company’s activities

According to IAS 34 – Interim Financial Reporting, an entity whose business is highly seasonal should present financial information for the twelve months up to the end of the interim period and additional comparative information for the prior twelve-month period in the interim condensed financial statements in order to provide a better understanding and comparison of its interim financial statements.

As mentioned in Note 15 Revenues and other income, as most of the income from the Company is generated by ongoing contracts that primarily depend on performance obligations not correlated to seasonal trends, it is considered that the Company activities are not seasonal.

F-7


Therefore, the following interim condensed financial statements and corresponding notes will not include comparative information other than that mentioned in IAS 34-20.
Statement of compliance and basis of presentation

The interim condensed consolidated financial statements have been prepared in accordance with IFRS, International Accounting Standards (“IAS”) as issued by the International Accounting Standards Board (“IASB”) as well as interpretations issued by the IFRS Interpretations Committee (“IFRS-IC”) and the Standard Interpretations Committee (the “SIC”), which application is mandatory as of June 30, 2021. The interim condensed consolidated financial statements are also compliant with IFRS as adopted by the European Union.

The accounting principles used to prepare the interim condensed consolidated financial statements for the six month period ended June 30, 2021 are identical to those used for the year ended December 31, 2020 except for the standards listed below that required adoption in 2021.
Application of New or Amended Standards and Interpretations

The Company adopted the following standards, amendments and interpretations whose application was mandatory for periods beginning on or after January 1, 2021:

Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16
Interest Rate Benchmark Reform – Phase 2

Flexibility measures relating to the accounting consequences of amendments to contracts following the reform of reference rates and hedge accounting criteria
Amendment to IFRS 16
Amendments for COVID-19 related to rent concessions

The application of these standards and these amendments had no impact on the interim consolidated condensed financial statements of the Company.

Early application of New or Amended Standards and Interpretations

The Company elected not to early adopt the new standards, amendments and interpretations, which application was not yet mandatory for the six month period ended June 30, 2021.

IFRS 17
Insurance contracts and related amendments
Amendment to IAS 1
Classification of liabilities as current and non-current
Disclosure of significant accounting policies
Update of Practice Statement 2 "Making materiality”
Amendment to IAS 37
Onerous Contracts - Cost of Performing a Contract
Amendment to IFRS 3
Conceptual Framework
Amendment to IAS 8
Definition of an accounting estimate
Amendments to IAS 16
Property, Plant and Equipment: Proceeds before Intended Use

The expected impact of these standards on the consolidated financial statements is not significant.














F-8


3. Consolidated principles and methods

3.1 BASIS OF CONSOLIDATION

Consolidated entities

As of June 30, 2021, the consolidation perimeter is identical to that of December 31, 2020 as Nanobiotix S.A. has five wholly owned subsidiaries:

Nanobiotix Corp., incorporated in the State of Delaware in September 2014 and located in the USA,
Nanobiotix Germany GmbH, created in October 2017 and located in Germany,
Nanobiotix Spain S.L.U., created in December 2017 and located in Spain,
Curadigm SAS, created on July 3, 2019 and located in France, and
Curadigm Corp., created on January 7, 2020 and located in the USA.

Accordingly, the interim condensed consolidated financial statements as of June 30, 2021 include the operations of each of these subsidiaries, to the extent applicable, from the date of their incorporation.

Foreign currency transactions

The unaudited condensed consolidated financial statements are presented in euros, which is the reporting currency and the functional currency of the parent company, Nanobiotix S.A.

The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate at the date of the statement of financial position and for the statement of operations, statement of comprehensive loss and statement of cash flow items at the average rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period.

The dollar-to-euro exchange rate used in the interim condensed consolidated financial statements to convert the Group transactions denominated in US dollars were $1.1884 as of June 30, 2021 and an average of $1.2053 for the six month period ended June 30, 2021 (source: Banque de France) compared with $1.1198 and $1.1015 as of and for the six month period ended June 30, 2020, respectively.

The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment.

3.2. USE OF JUDGEMENT, ESTIMATES AND ASSUMPTIONS

The preparation of interim condensed consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change.

Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. A sensitivity analysis may be presented if the results differ materially based on the application of different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the fair value of financial instruments.

Measurement of share-based payments

The Company measures the fair value of stock options (OSA), founders’ warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (e.g., vesting terms) and market data (e.g., expected share volatility) (See Note 17 Share-based payments).

Deferred tax assets

Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company’s assets and liabilities that appear in its financial statements. The primary temporary differences are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes.

The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow income projections judged to be sufficiently reliable to be made, the Company has not
F-9


recognized deferred tax assets in relation to tax losses carry forwards in the statements of consolidated financial position.

Clinical trials accruals

Clinical trial expenses, although not yet billed in full, are estimated for each study and a provision is recognized accordingly. (See Note 13.1 Trade and other payables for information regarding the clinical trial accruals as of June 30, 2021 and December 31, 2020).

Revenue recognition

In order to determine the amount and timing of revenue under the contracts with PharmaEngine and LianBio, the Company is required to use significant judgments, mainly with respect to determining the timing of satisfaction of services provided to PharmaEngine and LianBio (see Note 15 Revenues and other income below for additional detail regarding the revenue recognition related to the new agreement with LianBio).

Fair value of financial instruments

The fair value measurement of the loan granted by European Investment Bank (‘‘EIB’’) requires the Company to assess the amount of additional interest (‘‘royalties’’, as defined by the royalty agreement with EIB) that will be due according to the loan agreement. The royalties will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to the Company’s consolidated annual sales turnover generated during a period of six years (“the royalty period”) commencing on January 1, 2021.

For purposes of measuring the fair value of the EIB loan, the Company forecasts the sales that it expects to generate during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market.

The estimation of the royalty amount was reviewed as of June 30, 2021, taking into account the Company’s last development schedule. (See Note 4 Significant transactions and Note 12 Financial liabilities for details about this loan and the accounting treatment applied).

4. Significant transactions

During the first half of 2021, the Company entered into a new partnership with LianBio (see Note 4.2. LianBio below). The other ongoing significant contracts as of June 30, 2021 are the same ones disclosed in the Consolidated Financial Statements as of December 31, 2020 of the Company and are disclosed again below.

4.1 PHARMAENGINE

In August 2012, the Company entered into a license and collaboration agreement with PharmaEngine, which provided for the development and commercialization of NBTXR3 by PharmaEngine throughout the covered Asia-Pacific countries.

In March 2021, the Company and PharmaEngine mutually agreed to terminate the License and Collaboration agreement.

During the six month period ended June 30, 2021, the Company paid a cumulative amount of $6.5 million to PharmaEngine in accordance with the termination agreement signed between the parties. PharmaEngine will receive additional payments of $1 million upon receipt by the Company of certain clinical study reports and of $5 million upon the second regulatory approval of NBTXR3 in any jurisdiction of the world for any indication. The Company has also agreed to pay royalties to PharmaEngine at low single-digit royalty rates with respect to sales of NBTXR3 in the Asia-Pacific region for a 10-year period beginning at the date of the first sales in the region. As of June 30, 2021, these future payments were not accrued because the triggering events have not occurred.

4.2 LIANBIO

In May 2021, Nanobiotix announced a partnership with LianBio a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize NBTXR3 into Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand.

LianBio will collaborate in the development of NBTXR3 in Asia Pacific, and contribute to patient enrollment in five future global registrational studies across several tumor types and therapeutic combinations. LianBio will also support the expansion of the global phase III registrational study in head and neck cancer into Greater China, while supporting longer term strategic alignment across multiple tumor indications and therapeutic combinations.

As of June 30, 2021, a non-refundable upfront payment of $20 million has been collected by the Company at the signature of the LianBio Agreement. The Company is entitled to receive up to an aggregate of $220 million in
F-10


potential contingent, development and commercialization milestone payments. Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. See Note 15 Revenues and other income.

4.3 FINANCING AGREEMENT WITH THE EUROPEAN INVESTMENT BANK (“EIB”)
In July 2018, the Company signed a non-dilutive financing agreement with the EIB to borrow up to €40 million in order to fund its research, development and innovation activities related to NBTXR3 in various therapeutic indications, subject to achieving a set of agreed-upon performance criteria.

In connection with this financing agreement, the Company also entered into a royalty agreement with EIB pursuant to which the Company is required, during a six-year royalty calculation period commencing on January 1, 2021, to pay (on each June 30 with respect to the preceding year within the calculation period, beginning as of June 30, 2022 based on the 2021 revenue) royalties to EIB. (See. Note 12 Financial liabilities).

4.4 COLLABORATION AGREEMENT WITH MD ANDERSON

In January 2019, the Company and the University of Texas MD Anderson Cancer Center announced a large-scale research collaboration.

The collaboration will support multiple Phase I/II clinical trials involving around 340 patients with NBTXR3 for use in treating several cancer types, including head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers.

As part of the funding for this collaboration, Nanobiotix is committed to pay approximately $11 million for those
clinical trials during the collaboration. An additional milestone payment will also be paid upon grant of the first regulatory approval by the Food and Drug Administration in the United States. See Note 21 Commitments.

As of June 30, 2021, the Company recorded a prepaid expense for an amount of €1.3 million. (See Note 8.2 Other current assets). The Company will recognize expenses in the income statement as patient recruitment progresses, with the first recruitments expected to begin in the second half of 2020.

5. Intangible assets

The change in intangible assets breaks down as follows:
(in thousands of euros)As of December 31, 2020IncreasesDecreases
Transfer
As of June 30, 2021
Patents65    65 
Software651 4   656 
Intangible assets in progress